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resumo 
 
 
A Doença de Alzheimer (DA) é uma doença neurodegenerativa caracterizada 
pela presença de placas senis extracelulares (PSs), compostas principalmente 
pelo péptido Abeta, pelas tranças neurofibrilhares intracelulares (TNFs) 
compostas pela Tau hiperfosforilada, e pela disfunção sináptica. Assim, na DA 
estão envolvidas proteínas cuja expressão está alterada como a proteína 
precursora de amilóide de Alzheimer (PPA) e Tau, sendo a análise proteómica 
destas proteínas de grande importância para o estudo da patologia em 
questão. A possibilidade de estudar a sinapse, assim como o seu conteúdo 
proteico através dos sinaptossomas constitui um modelo muito atrativo, uma 
vez que as suas características morfológicas e funcionais são preservadas 
após o isolamento. No presente estudo, foram testadas duas metodologias 
distintas para isolar sinaptossomas, o protocolo de gradiente de Percoll e o 
protocolo de gradiente de sacarose. Da análise bioquímica desses protocolos 
verificou-se que o protocolo de gradiente de sacarose é mais eficiente, tendo 
sido aplicado nos diferentes ensaios realizados. De modo a avaliar os efeitos 
do Abeta na fosforilação anormal de proteínas envolvidas na DA, neste estudo 
foram analisados os efeitos do Abeta na fosforilação da PPA e Tau, nos 
resíduos Thr668 e Ser262, respectivamente. Verificou-se que nas fracções 
sinaptossomais de córtex e hipocampo o Abeta provoca um aumento da 
fosforilação da PPA e da Tau nos resíduos em estudo, principalmente nas 
concentrações mais elevadas. Adicionalmente, e sabendo que a DA pode 
resultar do mau funcionamento de proteínas cinases e fosfatases, que podem 
levar à desregulação de vias de transdução de sinal, é também importante 
determinar quais dessas cinases e fosfatases estão envolvidas na 
desfosforilação dos resíduos Thr668 na PPA e Ser262 na Tau. Neste estudo, 
através da utilização de inibidores de fosfatases, o ácido ocadeico (AO) e a 
cantaridina (CT), observou-se um envolvimento da PP1 na desfosforilação da 
PPA e da Tau. No seu conjunto, os resultados obtidos sugerem que o Abeta 
pode estar envolvido na alteração de vias de sinalização que culminam na 
Doença de Alzheimer.  
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abstract 
 
Alzheimer´s disease (AD) is a neurodegenerative disorder characterized by the 
presence of extracellular senile plaques (SP) mainly composed by beta-
amyloid peptide (Abeta), intracellular neurofibrillary tangles (NFTs) comprising 
hyperphosphorylated Tau and by synaptic dysfunction. Thus AD involves 
altered expression of some proteins, like Alzheimer´s Amyloid Precursor 
Protein (APP) and Tau, and therefore proteomic studies are of paramount 
importance for AD pathology. The possibility to investigate the synapse and 
their proteomic content using synaptosomes is a very attractive model since 
they preserve morphological and functional characteristics of synapse. In the 
present study, were tested two different methodologies: Percoll gradient 
protocol and sucrose gradient protocol to isolate synaptosomes, and it was 
shown that sucrose gradient protocol is more effective, being this protocol 
chosen to perform the following experiments. Due to the key role played by 
Abeta and abnormal protein phosphorylation in AD, in this study we analyzed 
the Abeta effects on APP and Tau phosphorylation, at Thr668 and Ser262 
residues, respectively. We verified an increase in APP and Tau 
phosphorylation at these specific residues, for both cortical and hippocampal-
synaptosomal enriched fractions, upon Abeta treatment, specially with higher 
concentrations. Additionally, and knowing that possibly AD is caused by protein 
kinases (PKs) and protein phosphatases (PPs) imbalance, which alters crucial 
signal transduction pathways, therefore is very important to establish the PPs 
involved in APP (Thr668) and Tau (Ser262) dephosphorylation. We observed an 
involvement of PP1 on APP and Tau dephosphorylation. Taken together, these 
findings suggest that Abeta could deregulate some signaling cascades leading 
to Alzheimer´s disease. 
 
 
Evaluating the effects of Abeta using a synaptosomal model 
 
1 
 
Abbreviations 
 
Abeta Amyloid β-peptide 
AD Alzheimer´s disease 
ADAM A Desintegrin And Metalloproteinase 
ADP Adenosine diphosphate 
AICD Amyloid precursor protein intracellular domain 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor         
AP Amyloid plaque 
 Aph1 Anterior pharynx-defective 1 
APLP1 APP Like Protein 1 
 APLP2 APP Like Protein 2 
 APOE Apolipoprotein E 
 APP Alzheimer´s amyloid precursor protein 
APS Ammonium persulfate 
ATP Adenosine triphosphate 
BACE Beta-APP cleaving enzyme 
BCA Bicinchoninic acid 
 BSA Bovine serum albumin 
CaMKII Calcium/Calmodulin-dependent protein kinase 
cAMP Cyclic Adenosine Monophosphate 
cdc2 Cyclin dependent protein kinase 2 
cdc25 Cell division cycle 25 
cdk5 Cyclin-dependent protein kinase 5 
CKI Casein Kinase I 
 CKII Casein Kinase II 
 CNS Central Nervous System 
CSF Cerebrospinal Fluid 
 CT Computed Tomography 
CT Cantharidin 
 CTFα Carboxyl-terminal fragment α 
CTFβ Carboxyl-terminal fragment β  
DAG Dyacilglycerol 
 DC Dielectric constant 
 DSPases Dual Specificity Protein phosphatases 
DTT Dithiothreitol 
 Dyrk1A Dual-specific tyrosine (y) regulated kinase 1A 
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ECL Enhanced chemiluminescence 
EGTA Ethylene glycol tetraacetic acid 
EOAD Early Onset Alzheimer´s Disease 
ERK Extracellular signal Regulated MAP Kinase 
FAD Familial Alzheimer´s Disease 
FDG 18F-2-deoxy-2-fluoro-D-glucose 
GKAP Guanylate kinase-associated protein 
GPCR G-Protein Coupled Receptor 
GSK3 Glycogen synthase kinase-3 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
I1 Inhibitor 1 
 I2 Inhibitor 2 
 imAPP immature APP 
 IP3 Inositol triphosphate 
IR Insulin receptor 
 IRS Insulin receptor substrate 
JNK Jun N-terminal kinase 
KPI Kunitz-type serine protease inhibitor 
LB Loading buffer 
 LGB Lower gel buffer 
 LOAD Late Onset Alzheimer´s Disease 
MAP Microtubule Associated Protein 
MAPK Mitogen-activated protein kinase 
mAPP mature APP 
 MAPT Microtubule Associated Protein Tau 
MARK Microtubule affinity regulating kinase 
Mint Munc18-interacting protein 
MRI Magnetic Resonance Imaging 
mRNA Messenger RNA 
 MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Munc13 Mammalian homologues of the C.elegans unc-13 gene 
Munc18 Mammalian homologues of the C.elegans unc-18 gene 
Nct Nicastrin 
  NEP Nerve ending particles 
NFTs Neurofibrillary tangles 
NMDAR N-methyl-D-aspartate Receptor 
OA Okadaic acid 
 ON Overnight 
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P1 First pellet 
 P2 Second Pellet 
 PAGE Polyacrylamide-gel electrophoresis 
p-APP Phosphorylated Alzheimer´s amyloid precursor protein 
PDK1 Phosphoinositide dependent Kinase 1 
Pen-2 Presenilin enhancer 2 
PET Positron Emission Tomography 
PHF Paired Helical Filaments 
Pi Inorganic phosphate 
PI3K Phosphoinositide 3 Kinase 
PIB Pittsburgh compound B 
PIP2 Phosphatidylinositol (4,5) biphosphate 
PIP3 Phosphatidylinositol (3,4,5) triphosphate 
PK Protein Kinase 
 PKA Cyclin AMP-dependent protein kinase 
PKB Protein Kinase B 
PKC Protein kinase C 
 PLCβ Phospholipase C-β 
 PNS Peripheral Nervous System 
PP Protein Phosphatase 
PP1 Protein Phosphatase 1 
PP2A Protein Phosphatase 2A 
PP2B Protein Phosphatase 2B 
PP2C  Protein phosphatase 2C 
PP5 Protein Phosphatase 5 
PP6 Protein Phosphatase 6 
PPM Protein Phosphatase metal-dependent 
PPP Phosphoprotein Phosphatase 
PS1 Presenilin-1  
 PS2 Presenilin-2 
 PSD Post-synaptic density 
PSD-93 Post-synaptic density of 93 kDa 
PSD-95 Post-synaptic density of 95 kDa 
PSEN1 Presenilin-1 gene 
 PSEN2 Presenilin-2 gene 
 p-Tau Phosphorylated Tau protein 
PTEN Phosphatase and Tensin homolog 
PTP Protein Tyrosine Phosphatase 
Evaluating the effects of Abeta using a synaptosomal model 
 
4 
 
RIM Rab3-interacting molecule 
RNA Ribonucleic Acid 
 ROS Reactive Oxygen Species 
RT Room temperature 
S1 First supernatant 
 S2 Second supernatant 
 SAP90 Synapse Associated Protein of 90 kDa 
sAPP Secreted APP 
sAPPα Secreted APP α 
sAPPβ Secreted APP β  
SCAMPs Secretory carrier-associated membrane proteins 
SDS Sodium dodecyl sulfate 
Ser Serine  
  SHANK SH3 domain and ankyrin repeat domain 
SNAP-25 Synaptosome-associated protein of 25 kDa 
SNARE Soluble NSF attachment protein receptor 
SP Senile plaques 
 SPECT Single Photon Emission Computed Tomography 
SV Synaptic Vesicles 
 Syn Synaptosomes 
 TBS Tris buffered saline 
 TBS-T Tris buffered saline - tween 
 Thr Threonine 
 Tris Tris(hydroxymethyl)aminomethane 
Tyr Tyrosine 
  VAMPs Vesicle-associated membrane polypeptides 
UGB Upper gel buffer 
WR Working reagent 
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1.1 Alzheimer´s Disease 
 
In 1906, Alois Alzheimer, a German psychiatrist, identified and described a 
neuropsychiatric disorder that affect the elderly, which is known as Alzheimer´s disease 
(AD) (Irvine et al., 2008; Pleckaityte, 2010). AD is the most common form of dementia and 
is a chronic, irreversible and progressive neurodegenerative disorder. Clinically is 
characterized by deterioration of memory (inability to form new and to retrieve old ones), 
cognitive decline and behavioral changes resulting in dementia. This disease leads to 
death, usually within 7 to 10 years after diagnosis, but some patients live longer than 20 
years (Masters et al., 2006; Irvine et al., 2008; Crewes and Mashliah, 2010).  
       Currently, AD affects more than 24 million people worldwide, with 4.6 million new 
cases each year. In Portugal, 90000 people are affected by AD 
(www.alzheimerportugal.org/). Due to increasing of elderly population, it is expected that 
in 2050, 100 million of patients will develop this neurodegenerative disease (Wimo and 
Prince, 2010). Age is the biggest known risk factor, with the incidence of the disease 
increasing from one in ten of those over 65 years-old to almost half of those over 85 
years-old. Women are more affected by AD, for the simple reason that they live longer 
than men (Irvine et al., 2008).  
 
1.1.1 Hallmarks of Alzheimer´s Disease 
 
        Histopathologically, brain tissues from individuals affected with AD are characterized 
by the presence of two insoluble protein aggregates: β-amyloid plaques (APs), also called 
senile plaques (SPs) (Figure 1A), and neurofibrillary tangles (NFTs) (Figure 1B). 
Additionally, neuronal and synaptic loss in distinct brain areas, including neocortex and 
hippocampus, which in turn impaired synaptic contacts, are also characteristics of AD 
brains (Figure2; DeKosky and Scheff, 1990; Katzam and Saitoh, 1991).  
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Figure 1: The two main histopathological hallmarks of AD. A) Senile plaques (SPs) mainly composed by Abeta 
peptide. B) Neurofibrillary tangles (NFTs), which are composed by hyperphosphorylated forms of microtubule-
associated protein tau (MAPT). (Adapted from O´Brien and Wong, 2011). 
 
Figure 2: Normal brain and Alzheimer´s brain.  (Taken from www.alzheimerportugal.org/). 
 
 
 
 
 
 
 
 
 
 
 
 
 
        The SPs (Figure 1A) are largely insoluble spherical extracellular deposits, reaching up 
200µm of diameter, and are prevalent throughout the cortex and hippocampus of 
affected brains (Glenner et al., 1984). These deposits are composed of proteinaceous 
deposits made mostly of Abeta peptide, predominantly the Abeta1-42 form, which has 
more propensity to aggregate and form oligomers. These deposits are associated with 
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astrogliosis, microglia, and degenerating nerve terminals (dendrites and axons). Abeta 
peptide derives from proteolytic cleavage of Azheimer´s amyloid precursor protein (APP). 
In AD the accumulation of this peptide could result from an increased Abeta production 
and/or failure in clearance mechanisms (Pimplikar, 2009). 
       NFTs (Figure 1B) are intracellular aggregates of paired helical filaments (PHFs). PHFs 
are composed of abnormal hyperphosphorylated forms of microtubule-associated protein 
Tau (MAPT) mainly associated with smaller amounts of neurofilament protein, 
microtubule-associated proteins (MAPs), ubiquitin and APP (Yates and McLoughlin, 2007; 
Hooper et al., 2008).  
       Both SPs and NFTs are found only in the central nervous system (CNS) and  they can 
be visualized in post-mortem brain analysis, specifically in the cerebral cortex and 
hippocampus (Katzam and Saitoh, 1991) . This evaluation is crucial for the confirmation of 
AD diagnosis (Irvine et al., 2008). 
 
1.1.2 Classification of Alzheimer´s disease 
 
Alzheimer´s disease is a multifactorial disease, being AD patients classified in two 
main groups: sporadic or non-familial form (more common) and genetic or familial form 
(rare). Only 5-10% of the AD patients have a familial Alzheimer´s disease (FAD) and 90-
95% have a sporadic form of AD (Maccioni et al., 2001).  
The causes of the sporadic cases are unknown, however some risk factors have been 
associated with AD. The age is thought to be the most predominant risk factor, which 
leads to synaptic failure and neuronal damage in cortical areas of the brain that are 
crucial for memory and mental functions (Masters et al., 2006) . The presence of a 
specific allele in the APOE gene that encodes apolipoprotein E, a protein involved in lipid 
transport and metabolism, is considered a risk factor for AD, more precisely in late onset 
AD cases. In fact this gene has 3 major alleles: ε2, ε3 and ε4. This last variant increases the 
risk to develop AD (Masters et al., 2006).   
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The gender, decreased mental activity, level of education, viral infections and head 
trauma history are other risk factors that are relevant for the developing of AD. 
This type of disease could also be Late Onset Alzheimer´s Disease (LOAD), since it 
develops after the age of 65 years. LOAD does not show any overt pattern of familial 
segregation (Masters et al., 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In familial cases, the major risk factors are mutations in at least three genes: amyloid 
precursor protein (APP) located on chromosome 21, presenilin-1 (PSEN1) located on 
chromosome 14 and presenilin-2 (PSEN2) on chromosome 1 (Figure 4). They encode APP, 
presenilin-1 (PS1) and presenilin-2 (PS2) proteins, respectively (Masters et al., 2006). 
Genetic cases are characteristic of Early Onset Alzheimer´s Disease (EOAD), which 
develops before the age of 65 years-old, with more than half of all such cases transmitted 
Figure 3: Schematic representation of principal causes of Late Onset Alzheimer´s 
Disease (LOAD). The non-genetic causes (age, gender, level of education, history of 
head trauma) and presence of APOEε4 allele, results in increased Abeta production 
or failure of clearance mechanisms that ultimately leads to neurodegeneration. 
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as autosomal dominant trait. In the familial forms of EOAD (Figure 4), the mutations in 
APP or in PSEN1 and PSEN2 genes, are related to an increased accumulation of Abeta 
which is directly correlated with AD pathogenesis (Maccioni et al., 2001).  
However, besides these mutations and since mutations of APP, PSEN1 and 2 cannot 
explain all EOAD, is though that there are other undiscovered mutant genes that can be in 
the origin of some causes of AD. 
       Interestingly, the progression of AD is similar for both EOAD and LOAD (Sisodia and 
Tanzi, 2007; Irvine et al., 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        Genetic and sporadic causes of AD can interfere with signal transduction pathways 
leading to neurodegenerative conditions (Cong et al., 1993). However, other events could 
also be related with AD, resulting in abnormal protein processing, protein expression and 
subcellular localization. Abnormal phosphorylation of key control proteins has been 
Figure 4: Schematic representation of principal causes of Early Onset 
Alzheimer´s Disease (EOAD). The later result is the increased Abeta production 
that will aggregate to form Senile Plaques that ultimately leads to 
neurodegeneration. 
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detected in many cases of AD and is thought to underlie the associated cellular 
dysfunctions that are characteristics of this disease (da Cruz e Silva and da Cruz e Silva, 
2003) . 
 
1.1.2.1  Amyloid cascade hypothesis 
 
The amyloid cascade hypothesis defends that mismetabolism of APP, abnormal 
production, aggregation and deposition of Abeta are central mechanism to the AD 
pathogenesis, and that Abeta pathology, somehow leads to the Tau/NFT pathology 
(Figure 2 and 5; Karran et al., 2011). 
As mentioned before the genetic mutations on APP, PSEN1 and PSEN2 genes, 
increases the risk to develop AD, since these mutations cause an increase of Abeta 
production (Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1995). Also, 
the localization of APP gene on chromosome 21 provides a connection of the 
development of AD pathology in patients with Down´s syndrome (Sisodia and Tanzi, 
2007). These patients have an extra copy of chromosome 21 (trisomy) and therefore a 
third copy of APP gene, increasing the risk to develop AD because there is a higher Abeta 
production and deposition (Holtzman et al., 2000).  Another aspect that supports this 
hypothesis is the APOE gene that increases the risk to develop LOAD. This gene is 
associated with Abeta clearance mechanism, and when deregulated, an increase of Abeta 
production is verified (Holtzman et al., 2000).   
All this alterations cause Abeta accumulation, which results in neuronal death and, 
finally, in dementia (Karran et al., 2011). 
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Figure 5: Amyloid cascade hypothesis. Mutations on APP, PSEN1, PSEN2 and APOE genes are responsible for 
Abeta accumulation, which causes neuronal dysfunction and dementia (Adapted from Irvine et al., 2008; 
Karran et al., 2011). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
1.1.3 Stages of Alzheimer´s Disease 
 
        During the progression of AD symptoms, three stages can be distinguished: mild, 
moderate and severe.  In the first stage, patients manifest loss of memory, due to 
damage in hippocampal neurons (region of memory formation). In this stage, patients 
may forget words and names with increasing frequency and get lost even in familiar 
places. In the moderate stage, cortical regions, which are responsible for reasoning, are 
affected and AD patients may begin to lose their logical thinking and start to experience 
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some confusion. This stage is characterized by the difficulty of patients to recognize, 
identify family members and by changes in their personality. Finally, in the third stage, 
additional brain regions are damaged, resulting in loss of control of many normal 
physiological functions. AD patients are unable to take care of their daily living (feeding, 
hygiene, even walking) and lose their ability to speak coherently. Normally, the cause of 
death in AD cases result from deterioration of the brain’s capacity to control vital 
physiological functions (Kelly, 2008). 
 
1.1.4 Diagnosis and Treatment 
 
       AD is usually diagnosed clinically from the patient history, memory tests that can 
further characterize the state of the disease, clinical observations, based on the presence 
of characteristic neurological and neurophysiological features and by laboratory tests.             
      Currently, neuroimaging techniques are available to diagnose AD with high sensitivity 
and specificity. As imaging techniques can be referred Computed Tomography (CT), 
Magnetic Resonance Imaging (MRI), Single Photon Emission Computed Tomography 
(SPECT) and Positron Emission Tomography (PET) (Masters et al., 2006). All these 
techniques could be used to help in AD diagnose because they could exclude other 
cerebral pathologies. The detection of enlarged ventricular spaces is used to support the 
diagnosis of AD. For this purpose, MRI technique could be used to detect atrophy of 
specific brain regions that is a characteristic of AD patients (de Leon et al., 2004). PET 
exams allows for visualization of metabolism in various regions of the brain by using 18F-2-
deoxy-2-fluoro-D-glucose (FDG) as a surrogate marker of glucose metabolism. This is 
important because in patients with early AD, in some regions of brain, is detected a 
decreased metabolism of glucose (Masdeu et al., 2005). Recently, a new compound was 
discovered, called Pittsburgh compound B (PIB) and used in addition to PET in diagnosis. 
This compound is labeled with carbon-11 and has the capacity to cross the blood-brain 
barrier, binding to β-sheet-rich fibrils (amyloid deposits) in the brain parenchyma. Then 
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this marker could be detected by PET imaging. This is a promising in vivo technique that 
complements diagnosis of AD by detecting Abeta accumulation (Mathis et al., 2005).  
       Additionally, biochemical analysis of cerebrospinal fluid (CSF) are also available and 
the measurement of Abeta, total-Tau and p-Tau (phospho-Tau) in CSF, are some 
examples of methods that are being used as AD diagnosis tools (Irvine et al., 2008). 
However, full diagnosis is only confirmed after death. 
       Regarding to AD treatment, there is no effective treatment against progression of 
disease. The drugs available only delay worsening of symptoms. Different therapies are 
under development, including therapies that reduce Abeta and/or Tau deposition, 
therapies that improve memory by activating cholinergic neurotransmission and anti-
oxidants. 
 
1.2 Alzheimer´s Amyloid Precursor Protein (APP) gene family 
 
      The Alzheimer´s amyloid precursor protein (APP) gene was first identified in 1987. APP 
gene is located on chromosome 21 (21q21.2-3) in humans and encodes APP protein. This 
protein belongs to a protein family that includes APP like protein 1 (APLP1) and APP like 
protein 2 (APLP2) (Matsui et al., 2007). All are type I transmembrane proteins that are 
cleaved by a similar manner. However, only APP contain the sequence that encodes 
Abeta domain (Zhang et al., 2011). Therefore APLP1 and APLP2 are not Abeta precursors 
and their contribution to AD pathogenesis is by an indirect manner (Sisodia and Tanzi, 
2007). 
APP is ubiquitously expressed in several cell types, including Central Nervous System 
(CNS) cells, where is concentrated in neuronal synapses (Neve et al., 2000). 
 APP has a large hydrophilic aminoterminal domain projected toward the extracellular 
space, a single hydrophobic transmembrane domain consisting of 23 residues and a small 
carboxy-terminal cytoplasmic domain (Figure 6; Kang et al., 1987).  
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Figure 6: Representation of APP structure. APP has a large N-terminal ectodomain projected to extracellular space 
and a shorter C-terminal in cytoplasmatic domain. The region that will originate Abeta peptide is represented in red.  
(Adapted from Gandy, 2005).  
 
 
 
 
 
 
 
1.2.1 APP isoforms 
 
Alternative mRNA splicing of exons 7, 8 and 15 of APP gene result in at least 10 
isoforms, ranging from 365 to 770 amino acids (da Cruz e Silva and da Cruz e Silva, 2003). 
However, the major isoforms, which predominate in most tissues, are APP695, APP751 and 
APP770, containing 695, 751, and 770 amino acids, respectively (Figure 7; da Cruz e Silva 
and da Cruz e Silva, 2003). The APP695 isoform is highly expressed in neurons, while APP751 
and APP770 are highly expressed in non-neuronal cells (da Cruz e Silva and da Cruz e Silva, 
2003). The isoforms are frequently divided into Kunitz-type protease inhibitor domain-
containing isoform (APP-KPI+) or Kunitz-type protease inhibitor domain-lacking isoforms 
(APP-KPI-), which are generated by the alternative splicing of exon 7 (da Cruz e Silva and 
da Cruz e Silva, 2003). APP-KPI+ isoforms, including APP751 and APP770, have KPI domain 
and are the predominant isoforms expressed in non-neuronal cells under normal 
conditions (Tanzi et al., 1988) and APP-KPI- isoform, like APP695, has not KPI domain and is 
the predominant form produced by neurons and neuronal cells (Matsui et al., 2007). 
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Figure 8: Intracellular expression of APP isoforms in PC12 cells. imAPP, immature APP; mAPP, mature APP. 
(Adapted from da Cruz e Silva and da Cruz e Silva, 2003). 
Figure 7: Schematic representation of the predominant APP isoforms. Boxes with respective number are 
representative of the exons. The most abundant neuronal isoform is APP695, and differs from APP751 and APP770 
isoforms since it lacks the exons 7 and 8. The red region represents the Abeta peptide sequence encoded by the 
exons 16 and 17. (Adapted from da Cruz e Silva and da Cruz e Silva, 2003) . 
 
 
 
 
 
 
 
 
 
 
 
       APP-KPI- isoforms are enriched in AD brain, and for this reason, they are considered 
more amyloidogenic (Moir et al., 1998). The three main isoforms present in neuronal like 
cells (such as PC12 cells) are APP695, APP751 and APP770 in both mature and immature 
forms. The sizes of these isoforms are in between 100-140 KDa (Figure 8). 
 
 
 
 
 
 
 
 
 
       Despite the enormous efforts to determine APP functions they still unclear. However 
several functions have been described to APP that includes functions as a receptor, 
involvement in synaptogenesis process and cell adhesion, iron export, synapse formation 
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and neural plasticity. APP could also have neurotrophic and neuroprotective properties 
(Maccioni et al., 2001; Priller et al., 2006; Schmidt et al., 2008).  
 
1.2.2 APP Processing 
 
During APP processing, a set of proteases called α-, β- and γ-secretases are involved, 
and depending on the enzyme that is acting and the final products, two major pathways 
can be distinguished: non-amyloidogenic pathway and amyloidogenic pathway (Maccioni 
et al., 2001; Yates and McLoughlin, 2007). In non-amyloidogenic pathway there is no 
Abeta production. In this case, α-secretase cleaves within the Abeta sequence releasing 
the soluble extracellular APP domain (sAPPα) while the α-C-terminal fragment (CTFα), 
also known as C83, is kept attached to the membrane and is further cleaved by γ-
secretase complex generating the APP intracellular domain (AICD) and the p3 fragment 
(Figure 9). In this case, α-secretase has a neuroprotective action, because cleaves APP in 
position that prevents Abeta formation (Yates and McLoughlin, 2007). In amyloidogenic 
pathway, Abeta is produced by the action of β- and γ-secretases. Therefore, APP is first 
cleaved by the β-secretase, releasing a shorter variant of the soluble extracellular domain, 
sAPPβ and a CTFβ (C99) that is further cleaved by γ-secretase complex to produce AICD 
and Abeta (Figure 9; Yates and McLoughlin, 2007). Abeta production leads to Abeta 
monomer formation that will associate to form small oligomers that increase in size, 
leading to fibril formation, which culminates with SP formation (Irvine et al., 2008).  
APP processing is regulated by three proteases: α-, β- and γ-secretases.  α-secretase is 
a member of ADAM (a desintegrin and metalloproteinase) family of proteinases (Yates 
and McLoughlin, 2007); β-secretase has been identified as the aspartic protease BACE1 
(β-APP cleaving enzyme) with a close homolog termed BACE2 (Yates and McLoughlin, 
2007); and finally, γ-secretase is a multiprotein complex comprising at least four proteins: 
PS1 or PS2 (the catalytic component); nicastrin (Nct), a type I transmembrane 
glycoprotein; and Pen-2 and Aph-1, two transmembrane proteins (Yates and McLoughlin, 
2007; Bergmans and De Strooper, 2010). 
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Figure 9: Schematic representation of APP processing. Non-amyloidogenic pathway involves the action of both α- 
and γ-secretases, resulting in generation of sAPPα, AICD and p3 fragments. Amyloidogenic pathway involves the 
activity of both β and γ-secretases and results in generation of sAPPβ, AICD and Abeta fragments. These fragments 
can self-aggregate to form Senile plaques. The different parts of APP are represented. 
 
1.2.3 Abeta peptide   
 
Abeta is produced during normal cellular metabolism and depending on the site of γ-
secretase cleavage several species could be produced varying between 38 and 43 amino 
acids. These species have in overall around 4KDa (Haass et al., 1992 ). The two main forms 
of Abeta are composed by 40 amino acid residues (Abeta1-40) and 42 amino acid residues 
(Abeta1-42). The longer form of Abeta is more insoluble and increases the capacity to 
generate fibrils, self-aggregate and incorporate into SPs. For this reason, Abeta1-42 has a 
greater tendency to aggregate compared with Abeta1-40 and increased neurotoxicity in 
neuronal cells (Citron et al., 1996; Yates and McLoughlin, 2007). Neurotoxicity is the result 
of an imbalance between the production and clearance of Abeta, leading to progressive 
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accumulation of Abeta oligomers in the nerve terminal, which trigger a series of reactions 
like production of Reactive Oxygen Species (ROS), excitotoxicity mediated through 
elevated intracellular calcium (Ca2+), altered energy metabolism due to damaged 
mitochondria and inflammatory responses. These mechanisms may lead to oxidative 
stress, synaptic dysfunction, microgliosis and loss of specific neuronal cell populations 
either via activation of necrotic or apoptotic pathways (Masters et al., 2006).  
 
1.3 Tau biology and function 
 
Tau is a low molecular and multifunctional microtubule-associated protein (MAP). In 
humans, Tau protein is predominantly expressed in neurons of both peripheral (PNS) and 
central nervous system (CNS). At normal conditions, it bounds to microtubules 
(components of neuronal cytoskeleton), stabilizing their structure and maintaining 
internal architecture (Yates and McLoughlin, 2007).  
 
1.3.1 Tau isoforms 
 
Human Tau proteins are encoded by a single gene, microtubule-associated protein 
Tau (MAPT) gene, located on locus 17q21-22 at chromosome 17, which consists of 16 
exons. Tau is a family of six isoforms, ranging in length from 352 to 441 amino acids 
generated by alternative mRNA splicing of exons 2, 3 and 10 (Alonso et al., 2001). Tau 
isoforms can be distinguished by their composition of microtubule-binding domain and 
projection domain (Buee et al., 2000). Tau contains three or four C-terminal repeat 
domains (R1, R2, R3 and R4), encoded by exons 9, 10, 11 and 12, respectively. Each repeat 
domain consists of 18 amino acid sequence separated by less conserved 13 or 14 amino 
acid sequences. The sequence of 18 amino acids is responsible for binding to 
microtubules, promoting microtubule polymerization and stabilization. For this reason 
Tau isoforms with 4R (R1, R2, R3, R4) binds more efficiently to microtubules than the 
isoforms with 3R (R1, R3, R4) (Figure 10; Buee et al., 2000; Alonso et al., 2001).  
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Projection domain consists of the N-terminal part of protein Tau and is composed by 
none (0N),  29 (1N) or 58 (2N) amino acid sequences resulted from alternative splicing of 
exon 2 and exon 3, respectively (Figure 10). This domain projects from the microtubules 
and interacts with other cytoskeletal elements and plasma membrane (Buee et al., 2000). 
Tau proteins bind to spectrin and actin filaments and through these interactions, may 
allow microtubules to interconnect with other cytoskeletal components such as 
neurofilaments, which restrict the flexibility of the microtubules. (Buee et al., 2000; 
Alonso et al., 2001; Johnson and Stoothoff, 2004).  
 
 
 
 
 
 
 
 
 
 
As shown in the Figure 10, the different Tau isoforms are 4R2N, 4R1N, 4R0N, 3R2N, 
3R1N and 3R0N. The longest isoform has four repeats, two inserts and 441 residues. The 
shortest isoform is composed by three repeats, no inserts and possess 352 residues 
Figure 10: MAPT gene and its isoforms. MAPT gene located on the human chromosome 17 is transcribed into the 
corresponding nuclear RNA that after alternative splicing yields several Tau mRNAs. These mRNAs are translated 
and can originate 6 different Tau isoforms. These isoforms differ by the absence or presence of 29 (1N) or 58 (2N) 
amino acids inserts encoded by exon 2 (pink) and 3 (gray) in the amino terminal part, in combination with either 
three or four repeat regions in the carboxyl-terminal part. R1 (yellow), R2 (blue), R3 (purple) and R4 (red). (Adapted 
from Avila et al., 2004). 
 
Evaluating the effects of Abeta using a synaptosomal model 
 
25 
 
(Johnson and Stoothoff, 2004). The later smallest isoform is called fetal Tau and is found 
in fetal human brain. However, all isoforms are found in adult human brain. 
The six isoforms expressed in neurons are presented in Figure 11 and have molecular 
weight in between 50 and 75 KDa. 
 
 
 
 
 
 
 
 
1.4 Protein Phosphorylation 
 
Protein phosphorylation is an important reversible post-translational modification 
that regulates the structural and functional properties of proteins, and consequently, 
regulates protein activity, cell cycle, gene regulation, learning and memory (Johnson and 
Barford, 1993; Hunter, 1995). This modification is characterized by the addition of a 
phosphate group, provided by ATP, to a specific hydroxyl group of a serine, tyrosine or 
threonine residue of the protein. This reaction is catalyzed by protein kinases (PKs) and 
the addition of a phosphate group is responsible for a structural change because of its 
negative charge. Therefore the phosphorylation reaction can be reversed by a protein 
phosphatase (PP) that removes the phosphate from the protein (Figure 12).  
The level of protein phosphorylation is controlled by the opposing actions of PKs and 
PPs. Abnormal function of these proteins can cause several diseases by altering the 
phosphorylation of critical proteins in normal and abnormal cellular processes (Hunter, 
1995; Chung, 2009).  
 
Figure 11: Intracellular expression of the six Tau isoforms in normal adult human brain.  
(Adapted from Billingsley and Kincaid, 1997; Deshpande et al., 2008). 
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       Abnormal protein phosphorylation has been associated with several pathologies 
including AD, since it modifies substrates in various functions such as interaction with 
other proteins, subcellular localization, enzymatic activity, ligand binding, and other 
properties (Chung, 2009). In Table 1 are summarized the PKs and PPs that are thought to 
be involved in AD. 
 
 
 
 
 
 
 
 
 
 
Figure 12: Protein phosphorylation. Proteins are phosphorylated by protein kinases 
which remove a phosphate from ATP to a donor, whereas protein phosphatases remove 
the phosphate group from a protein resulting in dephosphorylation of that protein. 
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 Table 1: Protein kinases (PKs) and Protein phosphatases (PPs) with altered expression and/or activity in AD.  
(↑ increased, ↓ decreased) (Adapted from Chung, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein kinases such as Glycogen synthase kinase 3 (GSK3α and β), Cyclin-dependent 
kinase 5 (Cdk5), Dual-specific tyrosine (Y) Regulated Kinase 1A (Dyrk1A) and Mitogen-
Activated Protein Kinases (MAPKs), like c-Jun-N-terminal kinase (JNK), extracellular signal 
regulated MAP Kinase (ERK) and p38 are up regulated in their expression and activity in 
AD patients (Chung, 2009).  
      Relatively to protein phosphatases they can be classified into three main classes based 
on sequence, structure and catalytic site: phosphoprotein phosphatase (PPP) and protein 
phosphatase metal-dependent (PPM) families which are both Serine/Threonine protein 
phosphatases, and the protein tyrosine phosphatase (PTP) superfamily. The largest class 
of PPs is the PPP family and includes PP1, PP2A, PP2B, PP4, PP5 and PP7 whereas the PPM 
family comprises Mg2+-dependent enzymes such as PP2C and mitochondrial protein 
phosphatases. Members of the PTP superfamily are categorized as either classical PTPs or 
dual specificity protein phosphatases (DSPases). DSPases dephosphorylate the serines, 
threonines and tyrosines of a particular substrate and consist of cdc25 and phosphatase 
and tensin homolog (PTEN) (Tian and Wang, 2002; Chung, 2009).  
PKs 
↑ Glycogen synthase kinase 3 (GSK3) 
↑ Cyclin-dependent kinases (Cdc2 and cdk5) 
↑ Dual-specific tyrosine (Y) Regulated Kinase 1A (Dyrk1A) 
↑ Ca2+/Calmodulin-dependent protein kinase (CaMKII) 
↑ Casein Kinase I and II (CKI and CKII) 
↓ Cyclic-AMP-dependent kinase (PKA) 
↓ Protein Kinase C (PKC) 
↑ Protein kinase B (PKB or Akt) 
↑ Mitogen-activated protein kinases (MAPKs) 
PPs 
↓ Protein Phosphatase 1 (PP1) 
↓ Protein Phosphatase 2A (PP2A) 
↑ Protein Phosphatase 2B (PP2B or Calcineurin) 
↓ Protein Phosphatase 5 (PP5) 
↑ Cell division cycle 25A and 25B ( cdc25A and cdc25B) 
↓ Phosphatase and Tensin Homolog (PTEN) 
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      In order to determine which protein phosphatases are involved in dephosphorylation 
of proteins, some synthetic inhibitors commercially available could be used, as okadaic 
acid (OA) and cantharidin (CT), among others. OA and CT are both used to inhibit PP-
family Serine/Threonine protein phosphatases like PP1 and PP2A. OA is the most widely 
used inhibitor to study PP1 and PP2A, being able to inhibit other PPs as PP4, PP5 and PP6. 
Cantharidin could also be used to inhibit PP1 and PP2A, being a weak inhibitor of PP2B 
(Swingle et al., 2007). 
 
1.4.1 APP Phosphorylation 
 
APP contains several residues that can be phosphorylated in its cytoplasmic and 
ectoplasmic domains (Gandy et al., 1988; Knops et al., 1993). The following 
phosphorylation sites were recently shown to be phosphorylated in AD brains: Ser198, 
Ser206, Tyr653, Thr654, Ser655, Thr668, Ser675, Tyr682, Thr686 and Tyr687 (Figure 13; Lee et al., 
2003; Chung, 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Phosphorylation sites on APP cytoplasmic and ectoplasmic domains. (Adapted from Slomnicki 
and Lesniak, 2008). 
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A summary of the kinases responsible for APP phosphorylation are presented in Table 
2. However, the phosphorylation of some residues still unknown. Also, relative to APP 
dephosphorylation, there are no conclusive studies regarding the protein phosphatases 
involved.   
 
 
Table 2: APP phosphorylatable residues. The protein kinases (PKs) involved are also indicated (Tian and Wang, 2002; 
da Cruz e Silva and da Cruz e Silva, 2003; da Cruz e Silva et al., 2004; Chung, 2009). 
 
 
 
 
 
 
 
Phosphorylation of APP on Thr654 and Ser655 residues by PKC has a protective role 
against AD, by favoring the non-amyloidogenic pathway. The reduction of PKC activity in 
the brains of AD patients leads to amyloidogenic pathway, and for this reason, more 
Abeta is produced (Gandy et al., 1993). Another residue that has an important role in APP 
processing is Tyr682. This residue is necessary for interaction between APP and its binding 
partners, like Fe65, that are important to regulate APP metabolism. (Barbagallo et al., 
2010). The Thr668 residue of APP has also an important role in AD. This residue is localized 
in APP cytoplasmic domain and could be phosphorylated by various proline-directed 
protein kinases that are upregulated in AD, including Cdk5, GSK3β, JNK3 and Dyrk1A (Lee 
et al., 2003). Thr668 phosphorylation seemed to cause a conformational change in the APP 
backbone such that the interaction of APP with its binding partners is affected. Studies 
suggests that phosphorylation on Thr668 residue is elevated in AD brains, which is thought 
to cause an increase of Abeta peptide production, resulting in SP formation (Lee et al., 
2003). This residue is going to be object of study in this work. 
 
PKs APP Residues 
PKC, CaMKII Thr654, Ser655 
GSK3β, Cdk5, JNK3, Dyrk1A, Cdc2 Thr668 
 CKII Ser198 
CKI Ser206 
Abl, Trka Tyr682 
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1.4.2 Tau Phosphorylation 
 
In AD, Tau phosphorylation can occur in high degree. An imbalance between the 
activity of PKs and PPs can cause Tau hyperphosphorylation, which results in its 
dissociation of microtubules and disruption of axonal transport. The major kinases that 
phosphorylate Tau are GSK3 (GSK3α and GSK3β), Cdk5, Dyrk1A, CaMKII, PKA, PKC and 
microtubule-affinity-regulating kinase (MARK) (Johnson, 2006; Ryoo et al., 2007). To date, 
more than 39 phosphorylation sites have been identified in PFH-Tau, including serine and 
threonine residues (Figure 14; Kopke et al., 1993; Giese, 2009).  
 
 
 
 
 
 
 
 
 
 
Studies demonstrated that Tau hyperphosphorylation negatively regulates its ability 
to stimulate microtubule assembly, being for that reason, responsible for the loss of its 
biological function, gain on toxicity and aggregation into PHFs, which form NFTs (Liu et al., 
2005). In this work, Ser262 residue is going to be object of study. This residue is present in 
microtubule binding domain being important to maintain microtubule assembly. 
Hyperphosphorylation of Ser262 is responsible for disruption of microtubule assembly and 
self assembly of Tau into PHF, which can lead to AD.  
Figure 14: Tau phosphorylated residues already described on the longest Tau isoform. (Billingsley and Kincaid, 
1997; Pevalova et al., 2006).  
N2 
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As mentioned before, up-regulation of Tau kinases or down-regulation of Tau 
phosphatases result in Tau hyperphosphorylation in the brain. To elucidate the 
mechanisms of abnormal hyperphosphorylation, some studies have been performed, and 
allowed the identification of several kinases like GSK3, Cdk5, PKA and PKC as being 
responsible for Tau phosphorylation. These kinases modulate the proline-rich regions of 
Tau in vivo, either directly or indirectly (Johnson, 2006; Ryoo et al., 2007). Among these 
Tau kinase candidates, GSK-3β, Cdk5 and PKA have been most implicated in Tau 
phosphorylation, and consequently, in AD (Liu et al., 2006). 
The following table summarizes the Tau phosphorylation residues as well as the 
Kinases and Phosphatases involved. 
 
Table 3: Tau phosphorylatable residues. The protein kinases (PKs) and protein phosphatases (PPs) involved are also 
indicated.  (Billingsley and Kincaid, 1997; Liu et al., 2005; Pevalova et al., 2006). 
 
 
      GSK3β (also called Tau kinase I) is a multifunctional Serine/Threonine kinase expressed 
in brain at high levels, and it is localized in neurons where is also present the Tau protein. 
This kinase is involved in many cellular processes, including signaling pathways, metabolic 
control, apoptosis/cell survival, oncogenesis, memory impairment, increased production 
of Abeta, inflammatory response and in a wide range of diseases such as AD (Balaraman 
et al., 2006; Hooper et al., 2008). The activation of GSK3β depends on Tyrosine (Tyr) 
 Tau Residues 
P
K
s 
GSK3α Ser199, Ser202, Thr212, Thr231, Ser235, Ser262, Ser324, Ser356, Ser396, Ser404 
GSK3β Thr181, Ser199, Thr205, Ser214, Thr231, Ser262, Ser369, Ser413 
Cdk5 Ser195, Ser202, Thr205, Thr212, Thr217, Thr231, Ser235, Ser396, Ser404 
PKA Ser214, Ser262, Ser324, Ser356, Ser396/404, Ser409, Ser416 
PKC Ser324 
CaMKII Ser262, Ser356, Ser409, Ser416 
MARK Ser262 
JNK Thr181, Ser199, Thr205, Ser214, Thr231, Ser262 
Dyrk1A Thr181, Ser199, Thr205, Ser214, Thr231, Ser262 
P
P
s PP1 Ser199, Ser202, Thr231, Ser235, Ser262, Ser393, Ser404 
PP2A Ser46, Ser199, Ser202, Thr205, Ser214, Ser235, Ser262, Ser396, Ser404 
PP2B Ser202, Thr205, Thr181, Thr231, Ser235, Ser262   
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phosphorylation at residue 216 which increases GSK3 activity (Hooper et al., 2008).  
However, GSK3 phosphorylation at Ser9 and Ser389 residues by Akt, also known as protein 
kinase B (PKB), inhibits its activity (Grimes and Jope, 2001). GSK3β is associated with 
microtubules and when is overexpressed in cells, Tau phosphorylation state increases 
dramatically. Immunoblotting analysis revealed that this kinase is overexpressed in AD 
brains, resulting in hyperphosphorylation of Tau. Biological function of this protein could 
be lost, improving Tau filaments formation and aggregation into PHFs that are the main 
constituent of NFTs. This increases the toxicity and cell death (Figure 15; Lucas et al., 
2001; Johnson and Stoothoff, 2004). 
      Cdk5 (Tau kinase II) is the predominant Cdk in the brain. Is highly expressed in neurons 
and is  important to synaptic plasticity and neuronal development (Cicero and Herrup, 
2005). Cdk5 is responsible for the regulation of neurogenesis during neurodevelopment. 
This kinase is also important in a variety of cellular functions such as actin dynamics, 
microtubule stability, axon guidance, membrane transport and dopamine signaling 
(Dhavan and Tsai, 2001). Upon activation, Cdk5 can phosphorylate several proteins 
(Dhavan and Tsai, 2001).  Under neurotoxic conditions, p35 is proteolytic cleaved by 
calpain to generate p25, which causes aberrant Cdk5 activation and leads to abnormal 
phosphorylation of its substrates, such as Tau (Ahlijanian et al., 2000; Lee et al., 2000). In 
human AD brains, p25 expression and Cdk5 activity are increased compared with age-
matched control brains. Studies using  transgenic mice overexpressing p25, demonstrate 
Tau hyperphosphorylation,  neurofibrillary pathology, increased Abeta levels and 
neurodegeneration, most likely due to Cdk5-mediated phosphorylation of Tau (Cruz et al., 
2003).  
      Finally, PKA is regulated by intracellular concentrations of cAMP levels. When cAMP 
binds to PKA, this kinase is activated and can modulate Tau phosphorylation (Billingsley 
and Kincaid, 1997) .  
      Relatively to protein phosphatases, some of them are associated with 
hyperphosphorylation levels of Tau. Protein phosphatases responsible for Tau 
dephosphorylation are PP1, PP2A and PP2B (Avila et al., 2004). However, the major Tau 
phosphatases are PP1 and PP2A (Rahman et al., 2005). PP1 is a Serine/Threonine-specific 
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phosphatase that is highly enriched in dendritic spines. This phosphatase can be activated 
when Inhibitor 1 (I1) is dephosphorylated by PP2B. Altered PP1 activity may contribute to 
Tau hyperphosphorylation. PP2A is localized on microtubules and binds directly to Tau, 
being downregulated in AD brain, underlying hyperphosphorylation of Tau (Pevalova et 
al., 2006). The downregulation of this phosphatase can be the result of up-regulation of 
two PP2A inhibitors, I1 and I2 (Liu et al., 2005; Tanimukai et al., 2005; Gong and Iqbal, 
2008). Relatively to PP2B, this phosphatase is important to microtubules and 
microfilaments developing. An inhibition of this phosphatase causes a 
hyperphosphorylation of Tau. These phosphatases are able to dephosphorylate Ser262, 
which is a phospho site specific to AD and also is an important site for the binding of Tau 
protein to microtubules, and therefore of extreme relevance for AD pathology. (Pevalova 
et al., 2006).  
 
      Tau phosphorylation has a physiological role and is important for neurite outgrowth, 
axonal transport and microtubule stability. However, when there is an imbalance 
between phosphorylation and dephosphorylation its biological function is affected, 
resulting in pathological role in the cell. Tau suffers conformational changes from its less 
phosphorylated (microtubule-bound form) to its hyperphosphorylated form (self-
aggregated form) that is more pathogenic. This in turn, causes pathological Tau filaments 
formation, microtubule dysfunction and cell death (Figure 15; Ahlijanian et al., 2000; 
Maccioni et al., 2001; Bielska and Zondlo, 2006; Gong et al., 2006).  
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Figure 15: Tau phosphorylation plays both physiological and pathological roles in the cell. When the 
phosphorylation state of Tau (green lines) is appropriately coordinated, it regulates neurite outgrowth, axonal 
transport, microtubule stability and dynamics. In pathological conditions, there is an imbalance between 
phosphorylation/dephosphorylation of Tau. Aberrant Tau phosphorylation can cause Tau filament formation, 
disrupt microtubule-based processes owing to decreased microtubule binding and ultimately leads to cell death 
(Adapted from Maccioni et al., 2001). 
 
 
 
 
1.4.3 Influence of Abeta Peptide on APP and Tau phosphorylation 
 
      During APP processing multiple Abeta species could be produced, including soluble 
monomeric peptides (40 amino acids) and more insoluble peptides (42 amino acids). 
These last ones have more ability to aggregate into oligomeric form, stimulating the 
production of ROS, being more toxic (Lublin and Gandy, 2010). Some studies have already 
been done in order to identify the effect of Abeta on protein phosphorylation. However, 
understanding the mechanisms whereby Abeta oligomers impair synaptic function 
remains elusive. According to amyloid cascade hypothesis, Tau hyperphosphorylation 
could be caused by toxic oligomers constituted by aggregated Abeta peptide (Karran et 
al., 2011). Studies performed by Takashima et al. (1993) reported that Abeta and Tau 
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phosphorylation are related. In these experiments, primary cultures of embryonic rat 
hippocampus were treated with 20µM of Abeta1-43 peptide, and after 24 hours they 
observed an increase of 1.6 times in Tau phosphorylation compared to control cultures.  
(Takashima et al., 1993). If Abeta really promotes Tau phosphorylation, and in accordance 
with amyloid cascade hypothesis, extracellular Abeta may act through a transduction 
pathway to exert an effect on Tau protein and consequently lead to a loss of microtubule 
binding, destabilizing the cytoskeleton and affecting the entire neuron as a final result 
(Anoop et al., 2010). Another study, performed by Busciglio group in 1995 also showed a 
relation between Abeta and Tau phosphorylation. In this case, they used primary cultures 
of fetal rat hippocampal neurons and primary cultures of fetal human cortical neurons. 
The exposure of these cultures to Abeta1-42 at a final concentration of 20µM resulted in 
increased levels of Tau phosphorylation at Ser202 and Ser396/Ser404 residues. They also 
verified an increase in phosphorylated Tau in the somatodendritic compartment which 
indicates that normal axonal localization of Tau is altered after Abeta exposure. Finally, 
Busciglio et al. (1995) also saw incapacity of phosphorylated Tau to bind to microtubules 
(Busciglio et al., 1995).   
       In relation to APP is known that the level of phosphorylation is increased in AD brains. 
So, possibly Abeta may also be involved in APP phosphorylation, however there are no 
studies regarding this subject. A possible explanation is the fact that Abeta may promote 
the deregulation of some signaling cascades. Indeed, He et al. (2011), showed that the 
formation of SPs, could disturb intracellular calcium ions, affecting the signaling cascades 
that involve Ca2+ as a second messenger (He et al., 2011). Possibly, these changes in 
second messenger activity could affect protein phosphatases and kinases activity, which 
in turn could modulate the phosphorylation of APP (Gandy et al., 1993). Also, a study 
performed by Vintem et al. (2009) indicates that Abeta could inhibit PPs activity. Possibly, 
this inhibition may lead to an increase in phosphorylation of certain proteins, like APP. 
      So, whereas the influence of Abeta on APP phosphorylation remains an unknown field, 
some findings support a possible involvement of Abeta in Tau phosphorylation. 
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1.5 Synaptic Transmission 
 
Brain tissues are composed by two main cells types: neurons, which produce and 
conduct electrochemical impulses and supporting cells - glial cells, which assists the 
functions of neurons and are more abundant (Williams and Herrup, 1988; Fox, 2010). 
Human brain is composed of an estimated 1012 heterogeneous neurons that 
communicate through synapses (Pocklington et al., 2006). These communicative contacts 
between neurons can be electrical or chemical.  
In electrical synapses, adjacent cells are electrically coupled and join together by gap 
junctions, enabling the propagation of electrical impulses from one cell to another via 
direct and physical contact. These synapses are characterized by a relatively simple 
organization of membrane structure, presence of associated organelles, are less mutable 
(in terms of their function and molecular characteristics), and exhibit a decreased 
plasticity that typifies the chemical synapse (Zoidl and Dermietzel, 2002). 
Chemical synapses provide the transmission across the majority of synapses in the 
nervous system and they are characterized by the release of chemical neurotransmitters 
and neuropeptides from pre-synaptic terminals. Cell-cell communications that occurs by 
chemical transmission is characterized by complex protein-driven molecular mechanisms 
of synthesis, delivery, storage, docking, fusion, neurotransmitter release and reuptake 
(Dale Purves, 2004). In general, synapses are composed of three main components: a pre-
synaptic component (pre-synaptic ending, axon terminal), a synaptic cleft (20-30nM 
wide), and a post-synaptic component (dendritic spine). Pre and post-synaptic 
membranes are uniquely distinguishable by visible densities along their corresponding 
plasma membranes (Figure 16; Palay, 1958). 
 
Evaluating the effects of Abeta using a synaptosomal model 
 
37 
 
Figure 16: Electron micrograph of a chemical synapse. This image shows the 
synaptic vesicles at the end of the axon and the synaptic cleft. The synaptic vesicles 
contain the chemical neurotransmitter. The post-synaptic cell is also presented. 
(Taken from Fox, 2010)  .  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
       Typically, pre-synaptic ending is further distinguished from the post-synaptic 
component by the presence of neurotransmitter-filled synaptic vesicles. In response to 
pre-synaptic membrane depolarization, vesicles release their contents into the cleft 
through membrane-trafficking events. The pre-synaptic axon terminal, also called bouton, 
also contains other organelles such as mitochondria, smooth endoplasmic reticulum, 
microtubules and neurofilaments. The pre-synaptic membrane is variably populated by 
docking/fusion apparatus, ion channels, and other protein constituints (Palay, 1958). The 
major proteins that are in pre-synaptic ending are trafficking proteins, which include 
synaptobrevin (also called vesicle-associated membrane protein - VAMP) and 
synaptotagmin. A group of proteins are included in synaptic vesicle (SV), like 
synaptophysin, synaptogyrin and SCAMPs (secretory carrier-associated membrane 
proteins). SNARE complexes are also important because they are involved in membrane 
fusion and consequently in vesicles exocytose process. SNAPs (Soluble NSF Attachment 
Protein) are also present in pre-synaptic membranes. Another proteins present in pre-
synaptic terminal, that have a role in the recruit of SV to pre-synaptic membrane, are 
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mammalian Unc-13 homolog (Munc13), Rab3 and Rab3-interacting molecule (RIM) 
(Figure 17; Chua et al., 2010).  
      The post-synaptic membrane, particularly at the dendritic spine, is recognizable by a 
collection of dense material visible by electron microscopy on its cytoplasmic surface. This 
so-called post-synaptic density (PSD) is a specialization of the nerve cell sub-membrane 
cytoskeleton composed of granular/filamentous material. A subcellular fraction enriched 
in structures with PSD-like morphology has been shown to contain signal-transduction 
molecules though to regulate receptor localization and function in the CNS (Palay, 1958; 
Kennedy, 1993). In this case, the major proteins in synaptic transmission are proteins 
found in the core of the PSD, such as members of the PSD-95 (Post-synaptic density-95), 
SAP90 (synapse-associated protein of 90 KDa), GKAP (Guanylate kinase-associated 
protein, which is formed by SAP90/PSD-95) and SHANK (SH3 domain and ankyrin repeat 
domain) (Figure 17; Chua et al., 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: The architecture of a synapse.  The functioning of the excitatory synapse is regulated by protein-protein 
interactions. On the pre-synaptic side, synaptic vesicles are filled with neurotransmitters (NT) which are released to 
the synaptic cleft, and bind to NT receptors on post-synaptic side. This results in a different membrane potential 
and trigger a signal transduction cascade. In this schematic diagram is also represented, the principal proteins of pre 
and post-synaptic terminals (Adapted from Staple et al., 2000; Chua et al., 2010).  
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1.6 Synaptosomes 
 
The term “synaptosome” was first mentioned by Whittaker´s group in 1964 (Bai and 
Witzmann, 2007). Synaptosomes are membranous sacs that are obtained by subcellular 
fractionation techniques applied on homogenized nerve tissue. They contain the 
complete pre-synaptic terminal, including mitochondria and synaptic vesicles, along with 
the post-synaptic membrane and PSD. All the components involved in the formation and 
consolidation of synaptic contacts remain intact. For this reason, they are seen as an in 
vitro model to study synaptic transmission (Whittaker, 1993).  
Through proteomics analysis of synaptosomes, molecular markers and the molecular 
mechanisms underlying synaptic neurotransmission could be studied. Therefore, 
synaptosomes could be important to understand some neurodegenerative disorders, 
including  Alzheimer´s disease (Whittaker and Gray, 1962; Whittaker, 1993). 
Nerve terminals differ in their shape and size, in their content of vesicles, 
mitochondria and cytoskeletal elements, in the number and nature of connections to 
post-synaptic cells, and also, in their content of neurotransmitters (Whittaker, 1993). The 
pre-synaptic side contains specialized secretion machinery for activity-dependent release 
of neurotransmitters into the synaptic cleft. At the post-synapse neurotransmitter, 
receptors and the downstream signal apparatus are organized mainly by the PSD 
(Schrimpf and Meskenaite, 2005).   
For synaptosomes isolation, first the region of interest is dissected out from the brain 
and then is homogenized using an appropriate buffer and applying an appropriate 
mechanical force. This causes the nerve terminals, or boutons, to be torn away from their 
axons, post-synaptic and glial cells to which they were connected. The pre-synaptic 
membranes then reseal, and enclose the nerve terminal contents (cytoplasm, synaptic 
vesicles, mitochondria and cytoskeleton), within a membranous sac (Figure 18). After the 
isolation of synaptosomes the molecular machinery for the release, uptake and storage of 
neurotransmitters remain intact. Frequently, a part of the post-synaptic membrane and 
its post-synaptic density will remain attached to the pre-synaptic nerve terminal. During 
the homogenization, some nerve terminals can be destroyed, either because of their 
Evaluating the effects of Abeta using a synaptosomal model 
 
40 
 
shape and/or size, or because some or all of their contents will be lost before the pre-
synaptic membrane reseals. However, most of them remain with a form and with 
functions that closely mimic nerve terminals in vivo (Whittaker, 1993; Dunkley et al., 
2008). 
 
 
 
 
 
 
 
 
 
 
 
      
 
 
 
 
      Synaptosomes can be morphologically and functionally characterized. Morphologically 
they are characterized by the presence of one or more small mitochondria, presence of 
synaptic vesicles, and presence of lengths of characteristically electron-dense membrane 
resembling post-synaptic membranes (Whittaker, 1993). The morphology of 
synaptosomes can be observed via electron microscopy (Figure 19).  
 
 
 
 
 
Figure 18: Isolation of synaptosomes. After isolation of synaptosomes the molecular 
machinery for the release, uptake and storage of neurotransmitters remains intact.  
(Adapted from Smalla et al., 2004). 
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      Functionally, synaptosomes are characterized by their capacity to produce ATP; 
presence on their plasma membranes of functional ion channels, carriers and receptors 
which allow them to maintain membrane potentials and ion homeostasis; by the capacity 
of their synaptic vesicles to take up and release neurotransmitters; recycling process of 
their membranes by endocytosis; and by the presence of functional enzymes and proteins 
normally present within nerve terminals. However, synaptosomes do not contain the 
machinery to make new proteins (except within their mitochondria) and their capacity for 
repair is therefore limited to a few respiratory complex proteins. For this reason, 
synaptosomes cannot be used for RNAi experiments or DNA transfection (Dunkley et al., 
2008).  
       After the isolation of synaptosomes, if they are kept at 4oC and are provided with 
appropriate nutrients they can retain their function for many hours. If not appropriate 
mantained, they lose ATP rapidly (at 37oC), and lose their functions (Dunkley and 
Robinson, 1986; Whittaker, 1993). 
 
 
 
Figure 19: Morphology of synaptosomes via electron microscopy. (Taken from 
Smalla et al., 2004). 
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2 Aims of the Dissertation 
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AD is a neurodegenerative disease that involves altered expression of some proteins 
at synapse, like APP and Tau. The possibility to investigate the synapse and their 
proteomic content using synaptosomes is a very attractive model since these 
membranous sacs allow a direct study without the complications inherent of studying this 
in situ. For this reason this model was used in this work. However, to enable more 
efficient proteomic analysis using synaptosomes some techniques have been developed 
for the isolation of relative pure synaptosomes from rat brain. Using this proteomic 
approaches, the molecular causes of the two main hallmarks of AD, SPs and NFTs, could 
be investigated.  
The mechanism whereby Abeta induces synaptic dysfunction is not clearly known yet, 
and also the relationship between Abeta and Tau phosphorylation. 
Despite normal production of Abeta during APP processing, when neuronal machinery is 
exposed to high concentrations of Abeta during long periods of time, neurotoxicity is 
induced. So, the understanding of the main processes that are responsible for this 
neurotoxicity could be used to devise efficacious interventions, like in therapeutically 
field. 
      In this thesis, firstly, were tested and compared two different methodologies to isolate 
and purify synaptosomes: Percoll gradient protocol and sucrose gradient protocol. The 
method with better results in the enrichment of synaptosomal fraction was chosen to 
perform the following experiments. After that, was evaluated the effect of Abeta on APP 
and Tau phosphorylation, and also the protein phosphatases involved on APP and Tau 
dephosphorylation. 
 
Thus the specific aims of this dissertation are: 
 Compare two methodologies to isolate synaptosomes; 
 Determine the role of Abeta on APP and Tau phosphorylation; 
 Establish the protein phosphatases involved in APP and Tau dephosphorylation; 
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3 Materials and Methods 
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3.1 Antibodies 
 
       The following primary antibodies were used: mouse monoclonal  synaptophysin 
antibody (Synaptic Systems) directed against synaptophysin, a pre-synaptic marker; 
mouse monoclonal PSD-95 antibody (Millipore) a post-synaptic marker; mouse 
monoclonal ATP synthase α (BD Biosciences Pharmingen) which specifically acts as 
mitochondrial marker; rabbit polyclonal p-APP  Thr668 antibody (Cell Signalling), which 
detects APP phosphorylated at Thr668 residue; rabbit polyclonal p-Tau Ser262 antibody 
(Santa Cruz Biotechnology, Inc) directed against the phosphorylated Tau at Ser262 residue; 
mouse monoclonal Tau-5 antibody (Millipore) to detect all phosphorylated and non 
phosphorylated isoforms of Tau (total-Tau), rabbit polyclonal C-TERM antibody 
(Invitrogen), which detects all APP isoforms (holo-APP) and mouse monoclonal antibody 
(Invitrogen) against β-Tubulin. The primary antibodies are summarized in      Table 4. 
       For immunoblotting were used as secondary antibody, Horseradish peroxidase anti-
mouse and anti-rabbit (GE Healthcare), both used with a dilution of 1:5000. 
 
Table 4: Summary of primary antibodies used, as well, the respective target, isotype, dilution and the expected band 
size. 
Antibody Target Isotype Dilution 
Expected 
band size 
(KDa) 
Synaptophysin 
Synaptophysin (pre-
synaptic protein) 
Mouse (monoclonal) 1:5000 37 
C-TERM holo-APP Rabbit (polyclonal) 1:500 100-140 
PSD-95 
PSD-95 (pos-synaptic 
protein) 
Mouse(monoclonal) 1:500 95-100 
ATP synthase α Mitochondria Mouse (monoclonal) 1:10000 55 
Tau 5 total-Tau Mouse (monoclonal) 1:500 46-68 
p-Tau Ser262 p-Tau at Ser262  Rabbit (polyclonal) 1:500 46-68 
p-APP Thr668 p-APP at Thr668  Rabbit (polyclonal) 1:1000 100-140 
β-Tubulin β-Tubulin Mouse (monoclonal) 1:1000 50 
 
Evaluating the effects of Abeta using a synaptosomal model 
 
47 
 
3.2 Preparation of biological material 
 
       In this work synaptosomes were used as a model to perform the different 
experiments. Synaptosomal fractions were isolated from the homogenate of both rat 
cortex (cortical synaptosomes) and hippocampus (hippocampal synaptosomes). The 
homogenates were then subjected to a differential centrifugation and after to a gradient 
density centrifugation, obtaining the synaptosomal fraction. Two different gradient 
density methodologies to obtain synaptosomal fractions were tested: Percoll gradient 
protocol and discontinuous sucrose gradient protocol. After comparison the one with 
higher efficiency was selected to perform the following sets of experiments. 
 
3.2.1 Brain dissection and cortical and hippocampal homogenate preparation 
 
       Cortex and hippocampus were obtained from Wistar female rats brains (9-15 weeks). 
These animals were obtained from IBMC (Instituto de Biologia Molecular e Celular - 
Porto) and Harlan. Animals were housed under controlled environment, 26ºC under a 12 
hour light/dark cycle, with food and water available ad libitum.  
       These animals were sacrificed by rapid cervical dislocation followed by decapitation. 
After this step, cortex and hippocampus were quickly dissected out and placed in 
previous identified petri dishes with homogenizer buffer (0.32M sucrose, 0.05M Tris, 
0.002M EGTA, 0.001M DTT, pH 7.6, in Percoll gradient protocol and 0.32M sucrose, 
0.02M HEPES, 0.001M DTT, pH 7.4 and proper protease inhibitor, in sucrose gradient 
protocol). After cortex and hippocampus dissection, they were weighted and added to 10 
volumes (1g of tissue to 9 ml) of respective homogenizer buffer. Tissues were then 
divided into small portions with a scissor and then homogenized with a Potter-Elvehjem 
tissue homogenizer with 10-15 strokes at 500-800 rpm. Each homogenate was then 
transferred to the respective tube (falcons of 15 ml) to be further used in Percoll or 
sucrose gradient protocols (described below). At same time, an aliquot of each 
homogenate was collected to be further analyzed. 
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3.2.2 Obtention of synaptosomal fraction 
3.2.2.1  Percoll gradient protocol 
 
       After preparation of cortex and hippocampus homogenates, these were centrifugated 
at 3000xg during 10 minutes at 4ºC (Figure 20). The pellets (P1), contaminated by 
mitochondria and nucleus were discarded and the supernatants (S1) where the axonal 
terminals are present were collected to new tubes (falcons of 15 ml) and then 
centrifugated for 14000xg during 20 minutes at 4ºC. At the end of centrifugation, 
supernatants (S2) were collected and stored at 4ºC for further analysis, and the pellets  
collected (P2) were ressuspended in 1 ml of Percoll®45% (v/v) solution, prepared in Krebs 
buffer (0.14M NaCl, 0.005M KCl, 0.025M HEPES, 0.001M EDTA and 0.01M Glucose, pH 
7.4). The ressuspended pellet was then centrifugated at 14000xg during 2 minutes at 4oC 
(Figure 20). After centrifugation, the top layer that contains the synaptosomal fraction 
was collected with a Pasteur pipette to new tubes and the remaining fraction was 
collected to further analysis (S3). Then, the top layer collected was washed in 1 ml of 
Krebs buffer by centrifugation at 14000xg during 2 minutes at 4 ºC. This washing step was 
repeated twice (Protocol adapted from Rebola et al., 2005). 
 
3.2.2.2  Sucrose gradient protocol 
 
        As in the previous protocol, after preparation of cortical and hippocampal 
homogenates they were centrifugated at 1000xg during 10 minutes at 4oC (Figure 20). 
With a Pasteur pipette, supernatants (S1) were then collected to new tubes (falcons of 15 
ml) and centrifugated for 15000xg during 22 minutes at 4ºC, while pellet (P1) was 
discarded (contaminated with mitochondria and nucleus). At the end of centrifugation, 
supernatants (S2) were collected and stored at 4ºC for further analysis, and pellets (P2) 
were ressuspended in Krebs buffer (0.14M NaCl, 0.005M KCl, 0.025M HEPES, 0.001M 
EDTA and 0.01M Glucose, pH 7.4) until make up 3,4 ml. With a Pasteur pipette, the 
pellets were then put on top of a discontinuous sucrose gradient (3.4 ml of 1.2M sucrose 
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on the lower layer, 3.4 ml of 0.8M sucrose on the intermediate layer and finally, 3.4 ml of 
synaptosomes ressuspended in Krebs buffer).  Then, the pellets on top of sucrose 
gradient were centrifugated at 100000xg (32600 rpm) during 2 hours and 15 minutes at 
4oC. After centrifugation, the synaptosomes were collected from the interface of the two 
densities (Figure 20), using a Pasteur pipette and transferred to new identified tubes 
(Protocol adapted from Bai and Witzmann, 2007 ). 
 
 
 
 
 
 
Figure 20: Summary of the main steps of Percoll gradient protocol and Sucrose gradient protocol. Syn: Synaptosomal 
fraction; P1: Pellet of first centrifugation; P2: Pellet of second centrifugation; S1: Supernatant of first centrifugation; 
S2: Supernatant of second centrifugation and S3: Supernatant of third centrifugation.  
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3.3 Acetone protein precipitation 
 
       This methodology consists in addition of acetone to the sample which results in a 
decrease of dielectric constant (DC). Consequently the interaction between proteins 
increase, which allow them to precipitate. The acetone is used to purify proteins in a 
sample. Briefly, cold (-20oC) acetone was added to samples in four times the sample 
volume. They were vortexed and incubated ON at -20oC. The samples were then 
centrifugated at 14000xg during 10 minutes at 4oC. Supernatants were discarded carefully 
to avoid dislodgement of the protein pellet. The tubes were placed on a paper to allow 
the acetone to evaporate, during 30 minutes at room temperature. The pellets were 
further ressuspended on boiling 1% SDS and transferred to new 2 ml microtubes. They 
were boiled during 10 minutes and then stored at -20oC. Their protein content was 
determined using BCA assay (as described below). 
 
3.4 Treatment of synaptosomes with Abeta 
 
       To evaluate the effects of Abeta1-42 on APP and Tau phosphorylation, approximately 
2µg/µl of cortical and hippocampal synaptosomes were incubated with different 
concentrations of Abeta1-42 peptide: 0.25µM, 0.5µM and 2µM Abeta1-42. The experiments 
were always conducted in duplicate. To evaluate the test validity we added an extra 
condition (positive control), which consisted in a scrambled Abeta1-42 at 2µM. Abeta1-42 
stocks and scrambled Abeta1-42 were first prepared and used at 100µM. After Abeta1-42 
addition, synaptosomes were incubated at 37oC for 3 hours. After that period loading 
buffer (LB) was added to each tube. After mixing the samples they were boiled for 10 
minutes. Subsequently, the samples were analyzed by SDS-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE).  
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3.5 Treatment of cortical synaptosomes with protein phosphatase 
inhibitors 
 
       In order to establish the protein phosphatases (PPs) involved on APP and Tau 
dephosphorylation, synaptosomes were incubated with okadaic acid (OA) and cantharidin 
(CT), two well known PPs inhibitors (Table 5; Swingle et al., 2007).  
 
Table 5: Range of IC50 values of protein phosphatase inhibition. All values are expressed as nanomolar (nM). PP, 
Protein phosphatase; IC50, 50% inhibition concentration. (Adapted from Swingle et al., 2007). 
 Inhibition of Ser/Thr Protein Phosphatase activity (IC50) 
Compound PP1 PP2A PP2B PP4 PP5 PP7 
Okadaic acid (OA) 15-50 0.1-0.3 4000 0.1 3.5 >1000 
Cantharidin (CT) 1100 194 >10000 50 600 nd 
 
 
       Different stock solutions of OA (0.1µM, 10µM and 100µM) and CT (100µM) were 
prepared and different concentrations were tested: 0.1nM, 0.25nM, 50nM, 500nM and 
5000nM for OA and 100nM, 250nM, 500nM, 1000nM and 10000nM for CT.  
       Cortical synaptosomes were incubated with several OA and CT concentrations for 30 
minutes and 3 hours, at 37oC. Each 30 minutes the samples were mixed to avoid the 
formation of precipitate. After these periods of time, LB was added to each tube and a 
spin down was done. After mixing the samples they were boiled and stored at -20oC until 
further analysis by SDS-PAGE (as described below). 
 
3.6 MTT assay 
 
       MTT assay is a colorimetric assay used to evaluate cell viability. This methodology 
measures the activity of succinate dehydrogenase on the reduction of the yellow 
compound 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to 
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insoluble purple formazan. This is then solubilized with an organic solvent (isopropanol) 
to dissolve the insoluble purple formazan product. Then the absorbance was quantified 
by a spectrophotometer. The reduction of MTT only occur in metabolically active cells, 
and for this reason, the level of formazan formation is an indirect measure of cell viability. 
       For this assay cortical and hippocampal synaptosome-enriched fractions were used 
and was evaluated the effect of Abeta1-42 treatment on synaptosomal viability. The same 
Abeta1-42 concentrations were used as described above (0.25µM, 0.5µM and 2µM) and 
scrambled Abeta1-42 (2µM) was also used. The tubes were then incubated during 2 hours 
at 37oC. After this time, MTT 5mg/ml was added to each tube for a final concentration of 
0.5mg/ml, and further incubated for 1 hour at 37oC. Then, 0.04M HCl/isopropanol (4 ml 
of HCl in 100 ml of final volume of solution) was added in a 1:1 proportion to MTT. 
Formazan crystals were ressuspended until these crystals were completely dissolved and 
then, the tubes were centrifugated at 13000xg during 2 minutes. The supernatants were 
transferred to cuvetes, wrapped with parafilm and homogenized to be quantified on 
spectrophotometer at 570 nm. 
 
3.7 BCA protein quantification assay 
 
       The bicinchoninic acid (BCA) assay (Pierce) is a biochemical assay used to determine 
total protein content in a test sample. This method consists in a color change of the 
sample solution from green to purple in proportion to protein concentration. This assay is 
performed in two reactions. Firstly, Cu2+ is reduced to Cu+ by protein in an alkaline 
medium, which results in a light blue complex - biuret reaction (temperature dependent 
reaction).  This reaction occurs with high sensitivity. Then, the colorimetric detection is 
allowed through the colorimetric detection of Cu+ cation, that was formed in step one, by 
BCA. More precisely, the reaction of two molecules of BCA with one Cu+ ion, results in an 
intense purple-colored reaction product. The BCA/Cu+ complex is water-soluble and 
exhibits a strong linear absorbance at 562nm with increasing protein concentrations (over 
a working range between 20µg/ml to 2000 µg/ml). 
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       The standards were prepared in duplicate as described in Table 6. The final volume 
for each standard and sample was equal to 50 µl.  
 
Table 6: Summary of BCA standards preparation. BSA, bovine serum albumin; WR, working reagent; SDS, Sodium 
Dodecyl Sulfate. 
Standards BSA (µl) 10% SDS (µl) H2O (µl) Protein mass (µg) WR (ml) 
P0 0 5 45 0 1 
P1 1 5 44 2 1 
P2 2 5 43 4 1 
P3 5 5 40 10 1 
P4 10 5 35 20 1 
P5 20 5 25 40 1 
P6 40 5 5 80 1 
 
 
       After prepare BCA standards, the samples were prepared also in duplicate, using 5 µl 
of synaptosomes and 45 µl of 1% SDS (final volume of 50µl). Then, 1 ml of Working (WR) 
reagent was added to both standards and samples. WR was prepared adding 50 parts of 
reagent A to 1 part of reagent B. After that, all the tubes were vortexed and incubated at 
37ºC during 30 minutes. Then, the tubes were cooled at room temperature during 2/3 
minutes and the absorbances were measured at 562 nm using a spectrophotometer. A 
standard curve was prepared by plotting the optical density (OD) value for each BCA 
standard against its concentration. This standard curve allowed the determination of 
protein concentration of each sample.  
 
3.8 Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-
PAGE) and Electrotransference 
 
       SDS-PAGE is a technique commonly used to separate proteins based on their 
molecular weight. This method uses a discontinuous polyacrylamide gel as a support 
medium and Sodium Dodecyl Sulfate (SDS) to denature proteins. SDS is an anionic 
detergent that denatures proteins by wrapping around the polypeptide backbone, which 
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results in an unfolding and individual polypeptide. Therefore the SDS confers a net 
negative charge to the polypeptide in proportion to its length. This reaction occurs in 
presence of SDS when the samples are heated to 100oC. SDS-PAGE can thus be used to 
estimate relative molecular mass, to determine the relative abundance of major proteins 
in a sample and to determine the distribution of proteins among fractions. The migration 
of heavy molecules is slower, while the migration of light molecules is fast. 
       After preparing the samples, they were subjected to a 5%-20% gradient SDS-PAGE. 
First, gradient gels were prepared and then loaded between two glasses plates. These 
gels polymerized during 45 minutes at room temperature. Then, the stacking gel solution 
was prepared and loaded on the top of gradient gel. Subsequently, a comb was inserted 
into each “sandwich” and the gel was allowed to sit for at least 30 minutes at RT. 
       During the polymerization time, the samples were prepared by adding Loading Buffer 
(LB) to each tube. Then they were boiled for 5 minutes. After this, a spin down was done 
to each sample and then the samples were loaded into the wells. A molecular weight 
marker was also loaded (Precision Plus ProteinTM, Bio-Rad). Gels were run at 90 mA 
during approximately 3 hours. After running the proteins, they were electrotransferred to 
a solid support (nitrocellulose) for 18 hours at 200mA. After electrotransference the 
detection of the protein of interest was carried out by immunoblotting (as described 
below). 
 
3.9 Immunoblotting 
 
       Immunoblotting is a technique in which proteins are transferred from an 
electrophoresis gel to a support membrane (nitrocellulose sheets) and then probed with 
antibodies. In this process, transferred proteins become immobilized on the surface of 
the membrane in a pattern that is an exact replica of the gel. After electrotransference 
the detection of proteins is carried out using specific antibodies against the proteins of 
interest. The general protocol is similar to each antibody however some antibodies have 
specific recommendations (Table 7). 
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Table 7: General immunoblotting protocol used for each antibody. ON, overnight; RT, Room Temperature;min, 
minutes; h, hours. 
 
Blocking 
Agent 
Primary 
Antibody 
Washings 
Secondary 
Antibody 
Washings 
Detection 
method 
ATP-Synthase 
α 
- 5% low 
fat milk in 
1x TBS-T;-
-4h at RT. 
-3% low 
fat dry 
milk in 1x 
TBS-T; 
-4h at RT + 
ON at 4
o
C. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
-3% low  fat 
dry milk in 
1x TBS-T; 
-2 h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
ECL 
C-Terminal 
- 5% low 
fat milk in 
1x TBS-T; 
-4h at RT. 
-3% BSA in 
1x TBS-T; 
-4h at RT + 
ON at 4
o
C. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
-3% BSA in 
1x TBS-T; 
-2 h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
ECL Plus 
p-APP Thr668 
-5% BSA 
in 1x TBS-
T; 
-4h at RT. 
-3% BSA in 
1x TBS-T; 
-4h at RT + 
ON at 4
o
C. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
-3% BSA in 
1x TBS-T; 
-2 h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
ECL 
PSD-95 
- 5% low 
fat milk in 
1x TBS-T; 
-4h at RT. 
-3% low 
fat dry 
milk in 1x 
TBS-T; 
-4h at RT + 
ON at 4
o
C. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
-3% low  fat 
dry milk in 
1x TBS-T; 
-2 h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
ECL 
p-Tau Ser262 
-5% BSA 
in 1x TBS-
T; 
-4h at RT. 
-3% BSA in 
1x TBS-T; 
-4h at RT  
-1x TBS-T; 
-3 times; 
-10 min 
each. 
-3% BSA in 
1x TBS-T; 
-2 h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
ECL Plus 
Synaptophysin 
- 5% low 
fat milk in 
1x TBS-T; 
-4h at RT. 
-3% low 
fat dry 
milk in 1x 
TBS-T; 
-4h at RT + 
ON at 4
o
C. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
-3% low  fat 
dry milk in 
1x TBS-T; 
-2 h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
ECL 
Tau 5 
-5% BSA 
in 1x TBS-
T; 
-2h at RT. 
-3% BSA in 
1x TBS-T; 
-2h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
-3% BSA in 
1x TBS-T; 
-2 h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
ECL 
β-Tubulin 
- 5% low 
fat milk in 
1x TBS-T; 
-2h at RT. 
-3% low 
fat dry 
milk in 1x 
TBS-T; 
-2h at RT. 
-1x TBS-T; 
-3 times; 
-10 min 
each. 
-3% low  fat 
dry milk in 
1x TBS-T; 
-2 h at RT. 
1x TBS-T; 
-3 times; 
-10 min 
each. 
ECL 
 
       First, the membranes were rehydrated in 1x TBS during 10 minutes. After this, the 
membranes were blocked with 5% non-fat dry milk in 1x TBS-T or 5% BSA in 1x TBS-T 
(blocking solution) usually during 4 hours. This step allows that unoccupied protein-
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binding sites on the membrane are saturated to prevent non-specific binding of 
antibodies. Then, the membranes were probed for the protein of interest with a specific 
primary antibody, usually during 4 hours with agitation and then sit overnight (Table 7). 
The primary antibody solution is appropriated prepared according to respective dilution, 
Table 4. After the incubation period with primary antibody, membranes were washed 
three times, each one during 10 minutes with 1x TBS-T, and then were probed a second 
time with secondary antibody during 2 hours under agitation. The secondary antibody 
solution was used at 1:5000 and is diluted in 3% non-fat dry milk in 1x TBS-T or 3% BSA in 
1x TBS-T. This antibody was specific for the primary antibody. Membranes were then 
washed three times with 1x TBS-T, each during 10 minutes.  
       After this, the membranes were incubated 1 minute with ECL detection kit or 5 
minutes with ECL plus detection kit in a dark room. Then, the nitrocellulose sheets 
incubated with ECL were placed on an x-ray film cassette with a sheet of film on top of it. 
The cassette was closed during an appropriate time to obtain signal and then the film was 
developed and fixed with appropriate solutions. Films were dried and quantified 
subsequently.  
 
3.10 Quantification and statistical analysis 
 
       Quantitative analysis of immunoblots was performed using the Quantity One GS-800 
densitometry software (Bio-Rad). This software allows the quantifications of band 
intensity and correlates it to protein levels. Data are expressed as means±SEM of 
triplicate determinations, from at least three independent experiments. 
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4 Results 
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4.1  Comparison of two methodologies to isolate synaptosomes: Percoll 
gradient protocol versus Sucrose gradient protocol 
 
       The knowledge of the synaptic proteome is a field in rapid expansion. The study of 
various subproteomes from the synapse, using synaptosomes as a model of study, holds 
great promise for improving our understanding of the processes that control synaptic 
proteins in both normal and disease states. For this reason, altered expression of multiple 
proteins in AD makes this disease a good candidate for proteomic analysis. 
       The use of synaptosomes as an in vitro model to study the expression of some 
proteins that are altered in some disorders, such as in AD, has been improved by the 
development of procedures to isolate and purify nerve terminals from the brain. In this 
thesis we compared two different procedures for this purpose. Both start with differential 
centrifugation of the brain homogenate to isolate synaptosomes and after this step, 
synaptosomes were collected and subjected to two different purification procedures: 
Percoll gradient and to a discontinuous sucrose gradient. These two protocols were 
detailed previously on section 3.2.2.1 and 3.2.2.2, respectively.   
       During the isolation procedure using Percoll gradient protocol were taken seven 
aliquots (Hm, S1, S2, S3, S4, S5 and Syn) for being further analyzed and using sucrose 
gradient protocol were taken four aliquots (Hm, S1, S2 and Syn) for further analysis. After 
the isolation, all samples were precipitated with acetone, ressuspended in 1% boiling SDS 
and the protein content determined using the BCA method. The samples were further 
subjected to SDS-PAGE and then, the expression of various markers was evaluated by 
immunoblotting, using specific antibodies against pre and post-synaptic region and also 
mitochondria. The comparison between these two protocols was performed by analyzing 
in each fraction a pre-synaptic protein (Synaptophysin), a post-synaptic protein (PSD-95) 
and also the presence of mitochondria, using for this purpose ATP-Synthase α antibody 
(ATP-S α). All fractions were compared with the homogenate fraction (Hm) to which was 
attributed the relative value of 100% to each specific marker. The homogenate fraction is 
particularly interesting since give us the idea of the initial amount of each protein (before 
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the isolation procedure), while the other fractions give information regarding the 
isolation procedure. 
 
4.1.1 Isolation of cortical synaptosome-enriched fractions 
 
       Essentially, we summarize the main differences between these two protocols, 
through observation of the enrichment of some markers in different fractions collected 
during the isolation procedure and the results are presented in Figure 21.  
       For Percoll gradient protocol there is a decrease in synaptophysin (Synapt.) levels on 
synaptosomal fraction, when compared with the homogenate fraction (Hm). 
Unexpectedly from Hm to S1 the expression of this pre-synaptic marker decreases. In the 
following supernatants fractions (S2, S3, S4 and S5) a very low or no expression of 
synaptophysin was detected (Figure 21, A). However, observing the results for sucrose 
gradient protocol, we can observe that the levels of synaptophysin in synaptosomal 
fraction are very similar to those observed in homogenate fraction (Hm) and S1. The 
levels of synaptophysin on S2 fraction were very low, as expected (Figure 21, A).  
       As post-synaptic marker we analyzed the PSD-95 protein (Figure 21, B). Thus, for 
Percoll gradient protocol the expression of this protein showed the same behavior as 
synaptophysin. There is a decrease from Hm to the supernatants fractions (S1, S2, S3, S4 
and S5). The level of PSD-95 in synaptosomal fraction was approximately 70% from those 
observed initially in Homogenate. For sucrose gradient protocol there was a decrease of 
PSD-95 expression from Homogenate (Hm) to synaptosomal fraction. From Hm to S1 only 
a slight decrease was observed and no expression was detected in S2 fraction. The 
synaptosomal fraction expresses approximately 70% of PSD-95 when compared with 
homogenate fraction. Finally, we also analyzed the content of mitochondria using the 
ATP-Synthase α (ATP-S α) (Figure 21, C). In Percoll gradient protocol we observed a 
decrease in expression from Hm to S1 with no expression detected in S2 and S3 fractions. 
For Syn fraction, we verified that the levels of ATP-S α were around 90% to those 
observed initially in the homogenate. For sucrose gradient protocol, we observed that the 
levels of ATP-S α in synaptosomal-enriched fractions are quite similar to those observed 
in homogenate. 
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Figure 21: Comparison of Percoll gradient protocol (left) and sucrose gradient protocol (right) for the isolation of 
cortical synaptosomes-enriched fractions. (A) Relative expression levels of the pre-synaptic marker synaptophysin 
(Synapt.) in several fractions collected in both protocols.  (B) Relative levels of post-synaptic marker PSD-95 in several 
fractions collected in both protocols. (C) Relative levels of the mitochondrial marker ATP-synthase α (ATP-S α) in 
several fractions collected in both protocols. Hm: homogenate, S1: supernatant from the first centrifugation; S2: 
supernatant from the second centrifugation; S3: supernatant from the third centrifugation; S4 and S5: supernatants 
from the washing steps; Syn: synaptosomal-enriched fraction. Values shown represent percentage relative to control 
(Hm: homogenate). Data were obtained from one experiment (n=1). 
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      For Percoll gradient protocol, the homogenate is the fraction that has the highest level 
of the markers tested while in sucrose gradient protocol we verified that the levels of 
synaptophysin and ATP-S α in Syn fractions were very similar to those observed in 
homogenate. Regarding PSD-95 expression levels we observed that they decrease for 
around 70% of the initial values (homogenate) in both protocols.  
 
4.1.2 Isolation of hippocampal synaptosome-enriched fractions 
 
       For the isolation of synaptosome-enriched fractions from hippocampus we used the 
same methodology, and the results are presented in Figure 22. The same fractions were 
collected for each protocol during isolation procedure, only the starting material 
(hippocampus) is different. 
       For Percoll gradient protocol, we detected a strong decrease in the synaptophysin 
expression from Hm to S1 and S2. Unexpectedly, in the Syn fraction we did not detect 
synaptophysin. The results were similar with two other markers (PSD-95 and ATP-S α) 
analyzed. Observing the results for sucrose gradient protocol, considering the three 
markers analyzed (synaptophysin, PSD-95, ATP-S α) we observed the same behavior in all 
fractions. The Hm and S1 fractions have the same level of expression, and S2 have no 
expression, as expected. In synaptosomal fraction was observed an accentuated increase 
in the expression of the three markers analyzed.   
       With this hippocampal analysis, we can observe that sucrose gradient protocol 
provide a higher sensitivity, allowing an enrichment of protein content of synaptosomes, 
particularly pre and post-synaptic proteins. 
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Figure 22: Comparison of Percoll gradient protocol (left) and sucrose gradient protocol (right) for the isolation 
of hippocampal synaptosome-enriched fractions. (A) Relative levels of the pre-synaptic marker synaptophysin 
(Synapt.) in several fractions collected in both protocols. (B) Relative levels of post-synaptic marker PSD-95 in 
several fractions collected in both protocols. (C) Relative levels of the mitochondrial marker ATP-synthase α (ATP-
S α) in several fractions collected in both protocols. Hm: homogenate, S1: supernatant from the first 
centrifugation; S2: supernatant from the second centrifugation; S3: supernatant from the third centrifugation; S4 
and S5: supernatants from the washing steps; Syn: synaptosomal-enriched fraction. Values shown represent 
percentage of the control (Hm: homogenate). Data were obtained from one experiment (n=1). 
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4.2 Effect of Abeta1-42 treatment on synaptosome viability 
 
       To assess the degree of neurotoxicity induced in cortical and hippocampal 
synaptosomal-enriched fractions after the exposure to increasing concentrations of 
Abeta1-42 peptide (0.25, 0.5 and 2 µM) during three hours, we performed the MTT assay. 
As previously described in 3.6 section the scrambled Abeta1-42 (2µM) was also used. 
Therefore, two hours after the exposure of synaptosomes to Abeta1-42, 60 µl of MTT was 
added to each sample (final concentration in each sample of 0,5mg/ml). After MTT 
addition, the samples were placed again at 37ºC (in the dark) for another hour, allowing 
the reduction of MTT to formazan crystals by viable synaptosomes. After this period of 
time, the formazan crystals were solubilized adding 0,04M HCL/isopropanol solution. 
When solubilized, samples were analyzed spectrophotometrically at 570 nm. MTT results 
for cortical and hippocampal synaptosomes are shown in Figure 23 and Figure 24, 
respectively. The results are expressed relative to control (without Abeta treatment). 
 
4.2.1 MTT assay of cortical synaptosome-enriched fractions 
 
       In Figure 23 we observe that after 3 hours of exposure of cortical synaptosomes to 
increasing Abeta1-42 concentrations, no significant changes in viability are observed. 
Moreover, when the synaptosomes were incubated with scrambled Abeta1-42 (2 µM) no 
significant changes in viability were also observed. 
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       With this result, we could confirm that the exposure of cortical synaptosomes to 
Abeta1-42 peptide (all concentrations tested) did not affect their viability and therefore 
they are physiological active.  
 
4.2.2 MTT assay of hippocampal synaptosome-enriched fractions 
 
       The MTT assay of hippocampal synaptosome-enriched fractions produced the same 
pattern of results of cortical synaptosomes. There were no significant changes on 
synaptosome viability relative to control (without Abeta treatment) when they were 
incubated with the various Abeta concentrations. However, when the synaptosomes 
were incubated with the scrambled Abeta1-42 (2µM) a strong reduction on their viability 
was observed (around 70%). 
Figure 23: Viability of cortical synaptosome-enriched fractions after exposure to increasing 
concentrations of Abeta1-42 (0.25, 0.5 and 2 µM) and to scrambled Abeta1-42 (2µM) during three hours. 
The values are expressed in percentage relative to Control. Data were obtained from three experiments 
(n=3). Scrb, scrambled Abeta1-42. 
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4.3 Role of Abeta on APP and Tau phosphorylation 
4.3.1 Cortical synaptosome-enriched fractions 
 
       In order to determine the effect of Abeta on APP and Tau phosphorylation we 
incubated cortical synaptosome-enriched fractions with Abeta1-42 peptide with increasing 
concentrations (0.25, 0.5 and 2 µM) for three hours. We also included scrambled    
Abeta1-42 as a control, at a concentration of 2 µM. Following this period, cortical 
synaptosomes were harvested and analyzed by SDS-PAGE and immunoblotting, using for 
this purpose, p-APP (Thr668) antibody, holo-APP (C-Terminal) antibody, p-Tau (Ser262) 
antibody and total-Tau (Tau5) antibody. β-Tubulin was used as loading control.  
 
Figure 24: Viability of hippocampal synaptosome-enriched fractions after exposure to increasing 
concentrations of Abeta1-42 (0.25, 0.5 and 2 µM) and to scrambled Abeta1-42 (2µM) during three hours. The 
values are expressed in percentage relative to Control. Data were obtained from three experiments (n=3). 
Scrb, scrambled Abeta1-42. 
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4.3.1.1  APP phosphorylation in cortical synaptosome-enriched fractions 
 
       Observing the state of APP phosphorylation at Thr668 residue upon treatment for 
three hours with Abeta1-42 peptide, APP phosphorylation seems to increase with all Abeta 
concentrations tested. However, is higher with 0.5µM and 2µM Abeta1-42 concentrations 
(Figure 25). Regarding the levels of holo-APP we can observe that it slight decreases 
relative to Control. However, in order to have a clear idea of the phosphorylation pattern 
at Thr668 residue, we calculated the ratio of p-APP (Thr668) versus holo-APP (C-Terminal) 
and the graphic representation is presented in Figure 25. Analyzing the ratio we can see 
that the APP phosphorylation at Thr668 residue increases with Abeta treatment, being 
more evident with higher Abeta1-42 concentrations (0.5 and 2 µM). 
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4.3.1.2  Tau phosphorylation in cortical synaptosome-enriched fractions 
 
       Observing the effects of Abeta1-42 on Tau phosphorylation (Figure 26), we can realize 
that the phosphorylation of Tau at Ser262 residue increases with higher concentrations of 
Abeta1-42 (0.5 and 2µM). Regarding the levels of total-Tau we can observe that upon 
Abeta1-42 treatment they did not change in all Abeta concentrations tested. We also 
calculated the ratio of phospho-Tau (Ser262) versus total-Tau and we observed that 
Figure 25: Abeta effects on APP phosphorylation at Thr668 residue. Cortical synaptosome-enriched 
fractions were incubated at 37
o
C for t(ree hours widh ancreasing concendrations of Abeda1-42 ( .25, 0.5, 
2µM) afd with scrambled Abeta1-42 (2 µM). The synaptosomes were then harvested and analyzed by SDS-
PAGE and immunoblotting with p-APP (Thr668) antibody, which recognizes Thr668 residue; holo-APP        
(C-Terminal) antibody which recognizes holo-APP and β-Tubulin used as loading control. The graphic 
represents the ratio between phospho-APP at residue Thr668 and holo-APP. Values shown represent 
percentage relative to control. Data was obtained from triplicate experiments (n=3). 
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Abeta1-42 treatment affect Tau phosphorylation at Ser262 residue being this increase more 
evident for higher concentrations of Abeta (0.5 and 2µM). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Abeta effects on Tau phosphorylation at Ser262 residue. Cortical synaptosome-enriched 
fractions were incubated at 37
o
C for three hours with increasing concentrations of Abeta1-42 (0.25, 
0.5, 2µM) and with scrambled Abeta1-42 (2 µM). The synaptosomes were then harvested and analyzed 
by SDS-PAGE and immunoblotting with p-Tau (Ser262) antibody, which recognizes Ser262 residue; total-
Tau (Tau5) antibody which recognizes total-Tau and β-Tubulin used as loading control. The graphic 
represents the ratio between phospho-Tau at residue Ser262 and total-Tau. Values shown represent 
percentage relative to Control. Data was obtained from triplicate experiments (n=3). 
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4.3.2 Hippocampal synaptosome-enriched fractions 
 
       To evaluate the effects of Abeta on APP and Tau phosphorylation, hippocampal 
synaptosome-enriched fractions were also used. The procedures were similar to those 
described for cortical synaptosome-enriched fractions (section 4.3.1). 
 
4.3.2.1  APP phosphorylation in hippocampal synaptosome-enriched fractions 
 
       Analyzing the state of APP phosphorylation (Figure 27) we verified an increase in 
phosphorylation for the higher concentrations of Abeta1-42 specially with 2µM. Relative to 
holo-APP there is no change for all Abeta concentrations tested. The phospho-APP 
(Thr668)/holo-APP(C-Terminal) ratio was calculated and interestingly present the same 
pattern observed for APP phosphorylation in cortical synaptosomes. In overall, we can 
see that exposure of synaptosomes to Abeta1-42 affects APP phosphorylation, specifically 
on Thr668 residue, being more evident for the higher concentrations of Abeta1-42. 
       In overall, we observed that upon Abeta1-42 treatment of either cortical and 
hippocampal synaptosomes-enriched fractions an increase on APP Thr668 residue 
phosphorylation is observed, particularly with the two higher concentrations. 
 
 
 
 
 
 
 
Evaluating the effects of Abeta using a synaptosomal model 
 
70 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.2.2  Tau phosphorylation in hippocampal synaptosome-enriched fractions 
 
       The levels of Tau phosphorylation at Ser262 residue (Figure 28), revealed an 
accentuated increase with 0.5µM of Abeta1-42. However, no effect was observed for the 
other Abeta concentrations tested. The levels of total-Tau were quite similar in all 
concentrations tested. The phospho-Tau (Ser262)/total-Tau (Tau5) ratio was calculated 
Figure 27: Abeta effects on APP phosphorylation at Thr668 residue. Hipocampal synaptosome-enriched 
fractions were incubated at 37
o
C for three hours with increasing concentrations of Abeta1-42 (0.25, 0.5, 2µM) 
and with scrambled Abeta1-42 (2 µM). The synaptosomes were then harvested and analyzed by 
immunoblotting with p-APP (Thr668) antibody, which recognizes Thr668 residue; holo-APP (C-Terminal) 
antibody which recognizes holo-APP and β-Tubulin used as loading control. The graphic represents the ratio 
between phospho-APP at residue Thr668 and holo-APP. Values shown represent percentage relative to 
control. Data was obtained from duplicate experiments (n=2). 
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and shows an increase in Tau phosphorylation at Ser262 residue upon treatment with 
Abeta1-42 peptide at concentration of 0.5µM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Abeta effects on Tau phosphorylation at Ser262 residue. Hippocampal synaptosome-enriched 
fractions were incubated at 37
o
C for three hours with increasing concentrations of Abeta1-42 (0.25, 0.5 and 
2µM) and with scrambled Abeta1-42 (2 µM). The synaptosomes were then harvested and analyzed by SDS-
PAGE and immunoblotting with p-Tau (Ser262) antibody, which recognizes Ser262 residue; total-Tau (Tau5) 
antibody which recognizes total-Tau and β-Tubulin used as loading control. The graphic represents the ratio 
between phospho-Tau at residue Ser262 and total-Tau. Values shown represent percentage relative to 
Control. Data was obtained from duplicate experiments (n=2). 
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4.4 Protein phosphatases involved on APP and Tau dephosphorylation  
 
       In order to determine the Protein Phosphatases (PPs) involved in APP and Tau 
dephosphorylation, we used two well known PPs inhibitors, okadaic acid (OA) and 
cantharidin (CT) at different concentrations to specific inhibit PP1, PP2A and PP2B. 
Therefore, cortical synaptosome-enriched fractions were incubated with increasing 
concentrations of OA and CT, for 30 minutes and 3 hours. After incubation with these PPs 
inhibitors the synaptosome-enriched fractions were harvested and analyzed by SDS-PAGE 
and by immunoblotting with the same antibodies used for the previous section 4.3.         
β-Tubulin was used as loading control.  
       To determine the effect of OA on APP and Tau phosphorylation we used the following 
concentrations: 0.1, 0.25, 50, 500 and 5000nM. For Cantharidin (CT), the same 
methodology described for OA was used, except the concentrations: 100, 250, 500, 1000 
and 10000 nM. 
 
4.4.1 Effect of Okadaic acid and Cantharidin on APP phosphorylation 
4.4.1.1  Okadaic acid and APP phosphorylation 
 
       The results regarding the effect of OA on APP phosphorylation are presented in Figure 
29. We can observe that upon 30 minutes of exposure to increasing concentrations of OA, 
the levels of APP phosphorylation remains almost unchanged. However, three hours after 
OA treatment we can observe a visible increase for phosphorylation at three higher OA 
concentrations (50nM, 500nM and 5000nM). The levels of holo-APP did not dramatically 
change after 30 minutes and 3 hours of cortical synaptosomes treatment with OA. 
Observing the graphic representation of phospho-APP (Thr668)/holo-APP ratio, for 30 
minutes we can see that OA did not induce significant alterations in the level of APP 
phosphorylation. However, at the 3 hours time-point we can observe an increase in APP 
phosphorylation when PP1 is inhibited (50 and 500nM). Lower concentrations of OA (0.1, 
0.25nM), where PP4 and PP2A are inhibited, are not sufficient to induce alterations in the 
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phosphorylation levels of APP. However, exposure to 50, 500 and 5000nM of OA in fact 
induces a marked increase on APP phosphorylation, suggesting an involvement of PP1 on 
APP dephosphorylation at Thr668 residue since there is a reduced difference in 
phosphorylation between 500nM and 5000nM (where PP2B is inhibited). 
 
 
 
 
 
 
Figure 29: Effect of Okadaic acid on APP phosphorylation (Thr668 residue). Cortical synaptosome-enriched 
fractions were incubated at 37
o
C for 30 minutes and 3 hours with increasing concentrations of OA (0.1, 0.25, 
50, 500 and 5000nM). This fraction was harvested and analyzed by SDS-PAGE and immunoblotting with            
p-APP (Thr668) antibody, which recognizes Thr668 residue; holo-APP (C-Terminal) antibody which recognizes 
holo-APP and β-Tubulin that was used as loading control. The graphic represents the ratio between phospho-
APP at residue Thr668 and holo-APP. Values shown represent percentage relative to control. Data was obtained 
from triplicate experiments (n=3). 
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4.4.1.2  Cantharidin and APP phosphorylation 
 
       Observing the effect of CT on APP phosphorylation, we can realize that the level of 
phospho-APP (Thr668) for both 30 minutes and 3 hours slightly increased with higher 
concentrations (1000 and 10000nM). The holo-APP levels remain almost unchanged in 
the two time periods tested. We calculated the phospho-APP/holo-APP ratio and for 30 
minutes of CT exposure is observed an increase in phosphorylation for all concentrations, 
although more accentuated for the three last concentrations (500, 1000 and 10000nM). 
This is indicative of an involvement of PP1 on dephosphorylation of APP at Thr668 residue. 
However, upon 3 hours of exposure to CT, there are no significant changes relative to 
phosphorylation state, only a slight tendency to increase with the two higher 
concentrations (Figure 30).  
Figure 30: Effects of Cantharidin on APP phosphorylation at Thr668 residue. Cortical synaptosome-enriched 
fractions were incubated at 37
o
C for 30 minutes and 3 hours with increasing concentrations of CT (100, 250, 
500, 1000 and 10000nM). This fraction was harvested and analyzed by SDS-PAGE and immunoblotting with    
p-APP (Thr668) antibody, which recognizes Thr668 residue; holo-APP (C-Terminal) antibody which recognizes 
holo-APP and β-Tubulin used as loading control. The graphic represents the ratio between phospho-APP at 
residue Thr668 and holo-APP. Values shown represent percentage relative to Control. Data was obtained from 
duplicate experiments (n=2). 
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4.4.2 Effect of Okadaic acid on Tau phosphorylation 
 
       Regarding the effect of OA on Tau phosphorylation, we can observe that the levels of 
phospho-Tau (Ser262) for both 30 minutes and 3 hours, increased with higher OA 
concentrations (50, 500 and 5000nM). The total-Tau did not dramatically changed for 
both time-point analyzed. Observing phospho-Tau/total-Tau ratio, we can see that upon 
30 minutes of exposure to OA, there was an increase on Tau phosphorylation with 50 and 
500nM (where PP1 is inhibited) as well as with 5000nM (where PP2B is inhibited). 
However, since there is no significant increase on Tau phosphorylation between the last 
two concentrations we can say that only PP1 is involved on dephosphorylation of this 
residue. The results obtained for 3 hours also indicate an involvement of PP1 in 
dephosphorylation of Ser262 (Figure 31).  
Figure 31: Effects of Okadaic acid on Tau phosphorylation at Ser262 residue. Cortical synaptosome-enriched 
fractions were incubated at 37
o
C for 30 minutes and 3 hours with increasing concentrations of OA (0.1, 0.25, 50, 
500 and 5000nM). This fraction was harvested and analyzed by SDS-PAGE and immunoblotting with p-Tau (Ser262) 
antibody, which recognizes Ser262 residue; total-Tau (Tau5) antibody which recognizes total-Tau and β-Tubulin used 
as loading control. The graphic represents the ratio between phospho-Tau at residue ser262 and total-Tau. Values 
shown represent percentage relative to Control. Data was obtained from triplicate experiments (n=3). 
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5 Discussion 
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       Alzheimer´s disease is the most common form of dementia, having SPs and NFTs as 
main features. According to the amyloid cascade hypothesis, has been proposed that 
these two hallmarks are correlated. Abeta peptide results from the proteolytic processing 
of APP and can aggregate originating extracellular SPs.  This peptide could deregulate 
some signaling cascades and also the activity of some kinases and phosphatases, leading 
to hyperphosphorylation of Tau originating intracellular NFTs. Thus, the study of AD 
pathology involves the analysis of altered expression of proteins, and for this reason AD is 
a good candidate for proteomic research. The possibility to use synaptosomes as an in 
vitro model to study synaptic physiology and neurochemistry makes this model system an 
appropriate form to investigate synaptic dysfunction pathways and therefore to study AD 
pathology. The main characteristics that make synaptosomes a good model are the 
presence of a pre-synaptic side (mainly composed by synaptic vesicles, mitochondria and 
cytoskeleton proteins) and also a post-synaptic side. 
       To enable more efficient proteomic analysis using synaptosomes some techniques 
have been developed for the isolation of relative pure synaptosomes from rat brain. So, 
the first objective of this work was the comparison of two different methodologies to 
isolate synaptosomes: Percoll gradient protocol and sucrose gradient protocol, from both 
cortex and hippocampus tissues. During the isolation procedure, for each tissue were 
collected several fractions (Hm: Homogenate, Sn: Supernatants fractions and Syn: 
Synaptosomal fractions) that were further analyzed by SDS-PAGE and immunoblotting 
using different markers (Synaptophysin, ATP-synthase α and PSD-95). The evaluation of 
immunoblots allowed the determination of the yield and purity of each protocol. For 
cortex, using Percoll gradient protocol we observed that there was a decrease in all 
markers in synaptosomal fraction relative to control (Figure 21). Although, with sucrose 
gradient protocol the expression of synaptophysin and ATP synthase α were very similar 
to those observed in Homogenate, while a decrease was observed for PSD-95 (Figure 21).  
The decrease in PSD-95 levels in Syn fraction could be due to the loss of post-synaptic 
terminals during the centrifugation steps. Regarding the hippocampal synaptosomes, for 
Percoll gradient protocol no expression was detected for the three markers tested on 
synaptosomal fraction, indicating that the amount of the previous markers present in the 
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sample were below the limiar of detection meaning that this procedure failure in the 
isolation of hippocampal synaptosomes. However, in sucrose gradient protocol we 
observed an increase in the expression levels of all markers tested. This increase could be 
explained by the presence of more contaminants on homogenate fraction that also 
contains nuclei, cell debries and remains of meninges. After the centrifugation steps these 
contaminants were removed and we obtained relatively pure synaptosomal fractions, 
enriched in pre-synaptic and post-synaptic markers and also with some mitochondria. 
Also, very evident is the fact that with the Percoll gradient protocol (either in cortex and 
hippocampus) a huge amount of material is lost in the first centrifugation step, affecting 
obviously the final yield obtained with procedure that was more critical in the 
hippocampus. Although, our results are in accordance with some previous reports. 
Gredilla et al. showed that synaptosomal fractions contain significant amounts of 
mitochondria, since they are present in pre synaptic side. This localization facilitates the 
access to energy that is critical for exocytosis/endocytosis events of synaptic vesicles, 
being for this reason important for the maintenance of synaptic activity and the proper 
function of central nervous system (Gredilla et al., 2012). This enrichment in mitochondria 
is also supported by McClatchy group (McClatchy et al., 2007). Regarding to 
synaptophysin marker there are some studies that also confirm an enrichment in 
synaptosomal fraction relative to whole brain preparations (Wishart et al., 2007). Finally, 
for PSD-95, some groups also verified an increase in the immunoreactivity of this protein 
in synaptosomal fraction compared with control (Hm) (McClatchy et al., 2007). Taken 
together, our results indicate that sucrose gradient protocol allows a more efficient 
purification of synaptosomes than Percoll gradient protocol. Additionally, with sucrose 
gradient protocol we obtained more synaptosomes than with Percoll gradient protocol. 
Therefore this protocol was chosen to routinely isolate cortical and hippocampal 
synaptosomes needed for further experiments in our laboratory. However, more 
independent experiments must be performed to confirm these results and additional 
techniques would be used to further validate the comparison of these two 
methodologies. Among them electron microscopy will be used to characterize these 
fractions.  
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        The next aim was the evaluation of the effect of Abeta1-42 on APP and Tau 
phosphorylation. Prior to that, we tested if the different Abeta concentrations used (0.25, 
0.5 and 2µM) affect synaptosomal viability using a MTT assay. After the exposure of 
synaptosomes to Abeta1-42 we observed that cortical and hippocampal synaptosomes 
were viable since no significative changes relative to control were observed. Our results 
are supported by Canas et al., which obtained a reduction less than 10% when exposed 
hippocampal synaptosomes to 0.5µM Abeta1-42 during 2 hours (Canas et al., 2009). 
Another study also shows that exposure of synaptosomes to 1µM Abeta1-40 during 5 
minutes, 30 minutes, 1 hour and 4 hours do not change their viability (Uranga et al., 
2010). 
       Since with all Abeta1-42 concentrations tested the synaptosome-enriched fractions 
were viable we carried on with the following experiments and we determined the effects 
of Abeta1-42 on APP and Tau phosphorylation. For this purpose, we exposed cortical and 
hippocampal synaptosomes to increasing concentrations of Abeta1-42 (0.25, 0.5 and 2µM) 
and we verified that Abeta influences both APP and Tau phosphorylation. To study APP 
and Tau phosphorylation we considered two residues, Thr668 and Ser262 on APP and Tau, 
respectively. Thr668 has an important role in AD since when phosphorylated the 
interaction of APP with its partners is affected. Relative to Ser262, this is an important 
residue on Tau. It is present in microtubule binding domain and so it is crucial for 
microtubule assembly. For this reason, phosphorylation of these residues could affect 
APP and Tau functions, being relevant for AD. For cortical synaptosome-enriched 
fractions we observed an increase in APP phosphorylation for Thr668 residue, considering 
higher concentrations of Abeta1-42 (0.5 and 2µM) (Figure 25). For Tau phosphorylation at 
Ser262 residue it increases in a concentration-dependent manner, being much higher for 
2µM (Figure 26). Relative to hippocampal-enriched fractions phosphorylation of APP at 
Thr668 residue increases with higher concentrations of Abeta (0.5 and 2µM) (Figure 27). 
For Tau at Ser262 the phosphorylation increases substantially for 0.5µM Abeta1-42 (Figure 
28), while the phosphorylation pattern for the other concentrations remains similar to 
control. Interestingly is that the effect of Abeta on APP and Tau phosphorylation is similar 
in both cortical and hippocampal synaptosomes. All together the results confirm that 
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Abeta1-42 influence APP and Tau phosphorylation. The mechanism whereby Abeta 
influence protein phosphorylation is not full elucidated. However, is thought that Abeta is 
affecting some signaling cascades and in turn some PKs and some PPs, which cause 
abnormal protein phosphorylation (Figure 32).    
Figure 32: Schematic representation of possible signaling cascades that could be deregulated in the presence of 
extracellular Abeta, leading to APP and Tau phosphorylation. Abeta stimulation increases Cdk5 activity, due to 
the coupling of p25, increasing APP and Tau phosphorylation. Cdk5 also mediates p38 MAPK and JNK activation, 
which in turn could phosphorylate Tau and the latter also phosphorylate APP. The increase in Ca
2+
 influx activates 
PP2B, which in turn activates PP1 by dephosphorylation of inhibitor 1 (I1). Since PP1 is active, it could 
dephosphorylate CaMKII, being this kinase active to phosphorylate APP and Tau. The presence of Abeta could 
also inhibit Akt signaling, inhibiting Akt. Inactivate Akt (dephosphorylated state) is not able to phosphorylate 
GSK3β being this kinase active, causing the phosphorylation of APP and Tau. PP1 also plays an important role in 
GSK3β activation leading to an increase in phosphorylation. Although is not shown in the figure, PKA and PKC 
could phosphorylate Tau and the latter can also phosphorylate APP. APP phosphorylation originates senile 
plaques and Tau phosphorylation form NFTs, which results in neurodegeneration. NMDR: N-Methyl-D-aspartate 
(NMDA) receptor; GPCR: G protein coupled receptors; DAG: dyacilglycerol; PLC: phospholipase C-β; IR: Insulin 
receptor; AC: adenylate cyclase; PIP2: phosphatidylinositol (4,5)-biphosphate; PIP3: phosphatidylinositol (3,4,5) 
triphosphate; PDK1: phosphoinositide dependent kinase 1; PI3K: phosphoinositide 3 kinase. 
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       For APP phosphorylation, specifically at Thr668 residue, the principal signaling 
cascades involved culminate with GSK3β, CaMKII and Cdk5 activation, which in turn 
activate JNK (Table 2 and Figure 32). These activated kinases are able to phosphorylate 
APP leading to more Abeta production that ultimately leads to more SPs formation. 
Relative to Tau phosphorylation at residue Ser262, the principal signaling cascades involve 
CaMKII, Cdk5, GSK3 and p38 MAPK (activated by Cdk5). These kinases are able to 
phosphorylate Tau which may results in NFTs formation (Table 2 and Figure 32). As shown 
in Figure 32, APP and Tau phosphorylation could result from activation or downregulation 
of some signaling cascades, like PI3K/Akt. In this case, the presence of extracellular Abeta 
diminishes Akt phosphorylation causing the inactivation of this kinase. This inactivation 
causes the GSK3β activation, being this able to phosphorylate APP and Tau. A variety of 
second messengers (like cAMP, DAG, IP3 and Ca2+) and the multiplicity of signaling 
cascades that are thought to be involved in AD, makes the study of this disease a difficult 
task. 
       Once established that Abeta1-42 induces APP and Tau phosphorylation, we went on to 
study the protein phosphatases involved on APP and Tau dephosphorylation at Thr668 and 
Ser262 residues, respectively. Our experiments, using both OA and CT, revealed that the 
major PP involved in APP Thr668 residue dephosphorylation seems to be PP1. This result is 
in agreement with previous works performed in our laboratory where an inhibition of PP1 
was observed after treatment of cortical primary neuronal cultures also with OA and CT 
(Oliveira, 2011).  
       For Ser262 residue of Tau, the phosphorylation increased when PP1 was inhibited with 
OA, suggesting an involvement of this PP in Tau dephosphorylation (Figures 31). Previous 
works from our laboratory also indicates PP1 as the main PP involved on Tau 
dephosphorylation at this residue, using cortical primary neuronal cultures treated with 
OA (Martins, 2011). Additionally, Rahman et al. (2006), also show a decrease in PP1 
activity in AD brains and this fact is also supported by several reports (Rahman et al., 
2006; Swingle et al., 2007). Experiments done with rats, which were treated with 
intraventricular infusions of OA also showed an increase in Tau phosphorylation, and 
decreased activity of PP1 (Billingsley and Kincaid, 1997). 
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       In conclusion, these findings suggest an important role of PP1 on both APP and Tau 
dephosphorylation at Thr668 and Ser262 residues, respectively. Phosphorylation of APP at 
Thr668 may facilitates β-secretase activity leading to Abeta production and accumulation, 
which results in neuronal damage and consequently in AD. For this reason, 
dephosphorylation of APP by PP1 could have a protective role. Relative to Tau Ser262 is an 
important residue located on microtubule binding domain and essential to the 
maintenance of microtubule assembly. Thus, PP1 may also have an important role in 
preventing not only the disruption of microtubule assembly but also the self-assembly of 
Tau into PHFs.  
      Interestingly, previous reports from the laboratory by Vintem et al. (2009), also 
described an inhibition of different PP1 isoforms with Abeta (Abeta1-40, Abeta25-35 and 
Abeta1-42) at low micromolar concentrations both in vivo and ex vivo (Vintem et al., 2009). 
Taken together these results suggests that Abeta inhibits PP1 probably by Cdk5 pathway 
(Figure 32), favoring phosphorylation of some proteins such as APP and Tau. Thus, these 
findings are consistent with the pathological sequential events of Alzheimer´s disease and 
deserve further investigation. 
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6 Concluding Remarks 
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Comparison of methodologies to isolate synaptosomes 
 
 Sucrose gradient protocol allows a more efficient purification of synaptosomes 
than Percoll gradient protocol. 
 
Abeta Effects on APP and Tau phosphorylation 
 
 Abeta1-42 treatment of cortical and hippocampal synaptosome enriched fractions 
did not affect their viability; 
 Abeta1-42 affects the phosphorylation state of APP, for both cortex and 
hippocampus; 
 In cortex, Abeta1-42 affects Tau phosphorylation in a concentration-dependent 
manner. However, in hippocampus, only 0.5µM affects the phosphorylation state; 
 
Protein Phosphatases involved in APP and Tau dephosphorylation 
 
 PP1 is involved in APP and Tau dephosphorylation. 
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I. Synaptosome isolation  
→ Equipment 
 Yellowline (OST 20 digital) Homogeneizer; 
 Centrifuge 5810R (eppendorf); 
 Centrifuge 5417R (eppendorf); 
 Ultracentrifuge (Beckman Optima LE-80K, 80Ti rotor). 
 
→ Solutions 
2M Sucrose 
 Sucrose     68,46g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 40C. 
 
0,5M HEPES 
 HEPES     13,015g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 40C.  
 
0,01M Dithiothreitol (DTT) 
 DTT     0,03085g 
Mix until the solute has dissolved. Adjust the final volume to 20 mL deionised H2O and 
store at 40C. Discard the solution if it is stored for more than 24 hours. 
 
0,1M KCl 
 KCl     0,7456g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 40C. 
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0,01M Ethylenediamine tetraacetic acid (EDTA) 
 EDTA     0,3722g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 40C. 
 
0,02M Ethylene glycol tetraacetic acid (EGTA) 
 EGTA     0,7607g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 40C. 
 
0,2M Glucose  
 Glucose     3,6032g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 40C. 
 
2M NaCl 
 NaCl     11,688g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 40C. 
 
1M Tris 
 Tris     12,114g 
Mix until the solute has dissolved. Adjust the final volume to 100 mL deionised H2O and 
store at 40C. 
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Homogenizing buffer – Percoll gradient protocol 
 
 2M Sucrose solution           8 mL (0,32 M) 
 1M Tris solution                  2,5 mL (0,05 M) 
 0,02M EGTA solution          5 mL (0,002 M) 
 0,01 M DTT solution            5 mL (0,001 M) 
 
Prepare the solution just prior to use. Adjust the pH at 7.6 and store at 40C. 
 
Homogenizing buffer – Sucrose gradient protocol 
 2 M Sucrose solution              16 mL (0,32 M) 
 0,5 M HEPES solution              4 mL (0,02 M) 
 0,01 M DTT solution                10 mL (0,001 M) 
 
Prepare the solution just prior to use. Adjust the pH to 7.4 and after add 50 µl of protease 
inhibitor to each 50 ml of solution. Finally, store at 40C. 
 
Krebs buffer 
 2 M NaCl solution                         7 mL (0,14 M) 
 0,1 M KCl solution                         5 mL (0,005 M) 
 0,5 M HEPES solution                   5 mL (0,025 M) 
 0,01 M EDTA solution               10 mL (0,001 M) 
 0,2 M Glucose solution                5 mL (0,01 M) 
 
Prepare the solution just prior to use. Adjust the pH to 7.4 and store at 40C. 
 
Percoll® 45% (v/v) 
 Percoll                2.7 mL  
 Krebs Buffer      3.3 mL 
 
Add 2.7 mL of Percoll® to 3.3 mL of Krebs buffer, for a final volume of 6 mL. Prepare the 
solution just prior to use and store at 40C. 
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II. SDS-PAGE and Immunoblotting Solutions 
→ Equipment 
 Electrophoresis system (Hoefer SE600 vertical unit); 
 Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec); 
 Transfer electrophoresis unit (Hoefer TE42). 
 
→ Solutions 
LGB (Lower Gel Buffer) (4x) 
To 900 mL of deionised H2O add: 
 Tris     181.65g 
 SDS     4g 
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 1L 
with deionised H2O. 
 
UGB (Upper Gel Buffer) (5x) 
To 900 mL of deionised H2O add: 
 Tris      75.69g 
Mix until the solutes has dissolved. Adjust the pH to 6.8 and adjust the volume to 1L with 
deionised H2O. 
 
30% Acrylamide/0.8% Bisacrylamide 
To 70 mL od deionised H2O add: 
 Acrylamide         29.2g 
 Bisacrylamide    0.8g 
Mix until the solutes have dissolved. Adjust the volume to 100 mL with deionised H2O. 
Filter through a 0.2 µm filter and store at 40C. 
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10% APS (ammonium persulfate) 
In 10 mL of deionised H2O dissolve 1 g of APS. This solution should be prepared fresh 
before use. 
 
10% SDS (Sodium Dodedilsulfate) 
In 10 mL of deionised H2O dissolve 1 g of SDS. 
 
Loading Gel Buffer (4x) 
 1 M Tris solution (pH 6.8)          2.5 mL (250 mM) 
 SDS                                            0.8g (8%) 
 Glycerol                              4 mL (40%) 
 Beta-Mercaptoetanol                2 mL (2%) 
 Bromofenol Blue                  1 mg (0.01%) 
Adjust the volume to 10 mL with deionised H2O. Store in darkness at room temperature. 
 
1 M Tris (pH 6.8) solution   
To 150 mL of deionised H2O add: 
 Tris base       30.3g 
Adjust the pH to 6.8 and adjust the final volume to 250 mL. 
 
10x Running Buffer 
 Tris             30.3g (250 mM) 
 Glycine      144.2g (2.5 M) 
 SDS             10 g (1%) 
Dissolve in deionised H2O, adjust the pH to 8.3 and adjust the volume to 1L. 
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Resolving (lower) gel solution (for gradient gels, 60 mL) 
                                                                                       5%                           20% 
H2O                                                                 17.4 mL                   2.2 mL 
30% Acryl/0.8% Bisacryl solution               5 mL                        20 mL 
LGB (4x)                                                          7.5 mL                     7.5 mL 
10% APS                                                         150 µL                     150 µL 
TEMED                                                             15 µL                       15 µL 
 
Stacking (upper) gel solution (20 mL) 
                                                                                      3.5%                                                                                    
H2O                                                     17.4 mL                   
30% Acryl/0.8% Bisacryl solution               5 mL                         
UGB (5x)                                                          7.5 mL                      
10% APS                                                          150 µL   
10% SDS                                                          200 µL 
TEMED                                                             25 µL                       
          
1x Transfer Buffer 
 Tris                    3.03g (25 mM) 
 Glycine              14.41 (192 mM)           
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume to 800 
mL with deionised H2O. Just prior to use add 200 mL of methanol (20%). 
 
10X TBS (Tris buffered saline) 
 Tris        12.11g (10 mM) 
 NaCl       87.66 (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O. 
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10x TBS T (TBS+Tween) 
 Tris                  12.11g (10mM) 
 NaCl                87.66g (159 mM) 
 Tween 20       5 mL (0.05%) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1L with deionised H2O. 
 
Membrane stripping solution (500 mL) 
 Tris-HCl (pH 6.7)              3.76 g (62.5 mM) 
 SDS                                     10g (2%) 
 Beta-mercaptoetanol     3.5 mL (100 mM) 
Dissolve Tris and SDS in deionised H2O and adjust with HCl to pH 6.7. Add the 
mercaptoethanol and adjust volume to 500 mL. 
 
 
